Signal	O
transduction	O
abnormalities	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
advanced	O
renal	O
carcinoma	O
:	O
clinical	O
relevance	O
and	O
effects	O
of	O
cytokine	B-protein
therapy	O
.	O

Studies	O
have	O
demonstrated	O
abnormalities	O
of	O
the	O
CD3/T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
and	O
pathways	O
of	O
signal	O
transduction	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
animals	O
and	O
patients	O
with	O
advanced	O
malignancy	O
.	O

Diminished	O
expression	O
of	O
TCRzeta	B-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
that	O
are	O
associated	O
with	O
the	O
TCR	B-protein
and	O
reduced	O
nuclear	O
localization	O
of	O
RelA	B-protein
containing	I-protein
nuclear	I-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NFkappaB	I-protein
)	I-protein
complexes	I-protein
have	O
been	O
noted	O
.	O

These	O
defects	O
have	O
been	O
described	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
patients	O
with	O
malignant	O
melanoma	O
,	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
,	O
ovarian	O
cancer	O
,	O
and	O
colorectal	O
cancer	O
.	O

Preliminary	O
observations	O
also	O
indicate	O
possible	O
correlation	O
with	O
clinical	O
variables	O
such	O
as	O
stage	O
in	O
selected	O
instances	O
.	O

To	O
further	O
characterize	O
altered	O
expression	O
of	O
TCRzeta	B-protein
,	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
,	O
and	O
impaired	O
activation	O
of	O
NFkappaB	B-protein
,	O
T	B-cell_type
lymphocytes	I-cell_type
were	O
obtained	O
from	O
65	O
patients	O
with	O
RCC	O
,	O
the	O
majority	O
of	O
whom	O
were	O
receiving	O
combination	O
cytokine	B-protein
therapy	O
[	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
,	O
IFN	B-protein
alpha	I-protein
-containing	O
regimens	O
]	O
and	O
37	O
control	O
individuals	O
.	O

In	O
29	O
of	O
these	O
patients	O
,	O
levels	O
of	O
TCRzeta	B-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
were	O
determined	O
by	O
Western	O
blots	O
of	O
T-cell	O
lysates	O
and	O
semiquantitated	O
using	O
densitometry	O
.	O

Relative	O
levels	O
were	O
then	O
correlated	O
with	O
a	O
series	O
of	O
clinical	O
variables	O
including	O
response	O
to	O
therapy	O
,	O
performance	O
status	O
,	O
survival	O
,	O
disease	O
sites	O
,	O
age	O
,	O
and	O
others	O
.	O

In	O
another	O
group	O
of	O
28	O
patients	O
(	O
three	O
individuals	O
from	O
the	O
first	O
group	O
)	O
,	O
the	O
frequency	O
of	O
abnormal	O
NFkappaB	B-protein
activation	O
was	O
studied	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
after	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
phorbol	O
myristate	O
acetate/ionomycin	O
or	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
.	O

Changes	O
in	O
these	O
signaling	O
molecules	O
during	O
cytokine	B-protein
treatment	O
were	O
also	O
investigated	O
.	O

TCRzeta	B-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
were	O
detected	O
in	O
the	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
27	O
of	O
29	O
patients	O
,	O
and	O
overall	O
,	O
reduced	O
levels	O
were	O
noted	O
visually	O
in	O
12	O
of	O
29	O
(	O
41	O
%	O
)	O
and	O
13	O
of	O
29	O
(	O
45	O
%	O
)	O
individuals	O
,	O
respectively	O
.	O

When	O
levels	O
were	O
semiquantitated	O
using	O
densitometry	O
,	O
significant	O
decreases	O
of	O
TCRzeta	B-protein
(	O
P	O
=	O
0.029	O
)	O
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
(	O
P	O
=	O
0.029	O
)	O
but	O
not	O
CD3epsilon	B-protein
(	O
P	O
=	O
0.131	O
)	O
,	O
compared	O
with	O
control	O
levels	O
,	O
were	O
found	O
.	O

In	O
patients	O
treated	O
with	O
IL-2/	O
IFN	B-protein
alpha	I-protein
-based	O
therapy	O
,	O
relative	O
levels	O
of	O
TCRzeta	B-protein
increased	O
significantly	O
(	O
P	O
=	O
0.002	O
)	O
on	O
day	O
15	O
of	O
cycle	O
one	O
compared	O
with	O
the	O
baseline	O
.	O

Correlations	O
of	O
TCRzeta	B-protein
or	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
levels	O
with	O
response	O
or	O
disease	O
variables	O
,	O
except	O
for	O
lower	O
TCRzeta	B-protein
levels	O
(	O
P	O
<	O
0.001	O
)	O
in	O
the	O
presence	O
of	O
bone	O
metastases	O
,	O
were	O
not	O
found	O
.	O

Abnormal	O
NFkappaB	B-protein
activation	O
after	O
stimulation	O
with	O
phorbol	O
myristate	O
acetate/ionomycin	O
and/or	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
was	O
found	O
in	O
59	O
%	O
of	O
patients	O
(	O
17	O
of	O
28	O
)	O
and	O
was	O
not	O
accounted	O
for	O
by	O
the	O
advanced	O
age	O
of	O
the	O
study	O
cohort	O
.	O

Activation	O
of	O
NFkappaB	B-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
inducible	O
during	O
cytokine	B-protein
therapy	O
in	O
four	O
of	O
six	O
individuals	O
who	O
displayed	O
impaired	O
NFkappaB	B-protein
activity	O
prior	O
to	O
therapy	O
.	O

Moreover	O
,	O
impaired	O
activation	O
of	O
NFkappaB	B-protein
does	O
not	O
appear	O
linked	O
to	O
a	O
reduction	O
of	O
TCRzeta	B-protein
expression	O
,	O
because	O
in	O
five	O
patients	O
,	O
normal	O
TCRzeta	B-protein
levels	O
were	O
present	O
although	O
kappaB	B-protein
binding	O
was	O
not	O
inducible	O
.	O

In	O
the	O
majority	O
of	O
patients	O
with	O
advanced	O
RCC	O
,	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
express	O
TCRzeta	B-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
,	O
and	O
in	O
a	O
subset	O
,	O
reduced	O
levels	O
of	O
these	O
TCRzeta	B-protein
associated	I-protein
molecules	I-protein
are	O
seen	O
that	O
may	O
increase	O
during	O
cytokine	B-protein
-based	O
therapy	O
.	O

Abnormal	O
activation	O
of	O
NFkappaB	B-protein
is	O
also	O
present	O
in	O
>	O
50	O
%	O
of	O
patients	O
and	O
may	O
also	O
revert	O
to	O
normal	O
during	O
IL-2/	O
IFN	B-protein
alpha	I-protein
-based	O
treatment	O
.	O

This	O
alteration	O
in	O
NFkappaB	B-protein
activation	O
occurred	O
in	O
the	O
presence	O
of	O
normal	O
expression	O
of	O
TCRzeta-associated	B-DNA
signaling	I-DNA
elements	I-DNA
.	O

The	O
clinical	O
significance	O
of	O
these	O
findings	O
remains	O
unclear	O
.	O

Vol	NULL
.	NULL

4	NULL
,	NULL
2337-2347	NULL
,	NULL
October	NULL
1998	NULL
Clinical	NULL
Cancer	NULL
Research	NULL
2337	NULL
Signal	NULL
Transduction	NULL
Abnormalities	NULL
in	NULL
T	NULL
Lymphocytes	NULL
from	NULL
Patients	NULL
with	NULL
Advanced	NULL
Renal	NULL
Carcinoma	NULL
:	NULL
Clinical	NULL
Relevance	NULL
and	NULL
Effects	NULL
of	NULL
Cytokine	NULL
Therapy	NULL
'	NULL
Ronald	NULL
M.	NULL
Bukowski	NULL
,	NULL
*	NULL
Patricia	NULL
Rayman	NULL
,	NULL
Robert	NULL
Uzzo	NULL
,	NULL
Tracy	NULL
Bloom	NULL
,	NULL
Kati	NULL
Sandstrom	NULL
,	NULL
David	NULL
Peereboom	NULL
,	NULL
Thomas	NULL
Olencki	NULL
,	NULL
G.	NULL
Thomas	NULL
Budd	NULL
,	NULL
Denise	NULL
McLain	NULL
,	NULL
Paul	NULL
Elson	NULL
,	NULL
Andrew	NULL
Novick	NULL
,	NULL
and	NULL
James	NULL
H.	NULL
Finke	NULL
Experimental	NULL
Therapeutic	NULL
Program	NULL
,	NULL
Cleveland	NULL
Clinic	NULL
Cancer	NULL
Center	NULL
[	NULL
R.	NULL
M.	NULL
B.	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
T.	NULL
O.	NULL
,	NULL
G.	NULL
T.	NULL
B.	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
J.	NULL
H.	NULL
F.	NULL
]	NULL
and	NULL
Departments	NULL
of	NULL
Immunology	NULL
[	NULL
R.	NULL
M.	NULL
B.	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
T.	NULL
B.	NULL
,	NULL
J.	NULL
H.	NULL
F.	NULL
]	NULL
,	NULL
Biostatistics	NULL
[	NULL
P.	NULL
E.	NULL
]	NULL
,	NULL
Hematology	NULL
and	NULL
Medical	NULL
Oncology	NULL
[	NULL
R.	NULL
M.	NULL
B.	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
T.	NULL
O.	NULL
,	NULL
G.	NULL
T	NULL
.	NULL

B	NULL
.	NULL
]	NULL

,	NULL
and	NULL
Urology	NULL
[	NULL
R.	NULL
M.	NULL
B.	NULL
,	NULL
R.	NULL
U.	NULL
,	NULL
A.	NULL
N.	NULL
,	NULL
J.	NULL
H.	NULL
F.	NULL
]	NULL
,	NULL
Cleveland	NULL
Clinic	NULL
Foundation	NULL
,	NULL
Cleveland	NULL
,	NULL
Ohio	NULL
44195	NULL
ABSTRACT	NULL
Studies	NULL
have	NULL
demonstrated	NULL
abnormalities	NULL
of	NULL
the	NULL
CD3/	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
and	NULL
pathways	NULL
of	NULL
signal	NULL
transduction	NULL
in	NULL
T	NULL
lymphocytes	NULL
from	NULL
animals	NULL
and	NULL
patients	NULL
with	NULL
advanced	NULL
malignancy	NULL
.	NULL

Diminished	NULL
expression	NULL
of	NULL
TCR	NULL
and	NULL
p56	NULL
``	NULL
that	NULL
are	NULL
associated	NULL
with	NULL
the	NULL
TCR	NULL
and	NULL
reduced	NULL
nuclear	NULL
localization	NULL
of	NULL
RelA	NULL
containing	NULL
nuclear	NULL
factor	NULL
Â«	NULL
B	NULL
(	NULL
NFB	NULL
)	NULL
complexes	NULL
have	NULL
been	NULL
noted	NULL
.	NULL

These	NULL
defects	NULL
have	NULL
been	NULL
described	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
malignant	NULL
melanoma	NULL
,	NULL
renal	NULL
cell	NULL
carcinoma	NULL
(	NULL
RCC	NULL
)	NULL
,	NULL
ovarian	NULL
cancer	NULL
,	NULL
and	NULL
colorectal	NULL
cancer	NULL
.	NULL

Preliminary	NULL
observations	NULL
also	NULL
indicate	NULL
possible	NULL
correlation	NULL
with	NULL
clinical	NULL
variables	NULL
such	NULL
as	NULL
stage	NULL
in	NULL
selected	NULL
instances	NULL
.	NULL

To	NULL
further	NULL
characterize	NULL
altered	NULL
expression	NULL
of	NULL
TCRL	NULL
,	NULL
p56	NULL
``	NULL
,	NULL
and	NULL
impaired	NULL
activation	NULL
of	NULL
NFKB	NULL
,	NULL
T	NULL
lymphocytes	NULL
were	NULL
obtained	NULL
from	NULL
65	NULL
patients	NULL
with	NULL
RCC	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
whom	NULL
were	NULL
receiving	NULL
combination	NULL
cytokine	NULL
therapy	NULL
{	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-2	NULL
,	NULL
IFNa-containing	NULL
regimens	NULL
]	NULL
and	NULL
37	NULL
control	NULL
individuals	NULL
.	NULL

In	NULL
29	NULL
of	NULL
these	NULL
patients	NULL
,	NULL
levels	NULL
of	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
were	NULL
determined	NULL
by	NULL
Western	NULL
blots	NULL
of	NULL
T-cell	NULL
lysates	NULL
and	NULL
semiquantitated	NULL
using	NULL
densitometry	NULL
.	NULL

Relative	NULL
levels	NULL
were	NULL
then	NULL
correlated	NULL
with	NULL
a	NULL
series	NULL
of	NULL
clinical	NULL
variables	NULL
including	NULL
response	NULL
to	NULL
therapy	NULL
,	NULL
performance	NULL
status	NULL
,	NULL
survival	NULL
,	NULL
disease	NULL
sites	NULL
,	NULL
age	NULL
,	NULL
and	NULL
others	NULL
.	NULL

In	NULL
another	NULL
group	NULL
of	NULL
28	NULL
patients	NULL
(	NULL
three	NULL
individuals	NULL
from	NULL
the	NULL
first	NULL
group	NULL
)	NULL
,	NULL
the	NULL
frequency	NULL
of	NULL
abnormal	NULL
NFB	NULL
activation	NULL
was	NULL
studied	NULL
using	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
after	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
phorbol	NULL
myristate	NULL
acetate/ionomycin	NULL
or	NULL
anti-CD3	NULL
mono	NULL
Received	NULL
4/3/98	NULL
;	NULL
revised	NULL
7/8/98	NULL
;	NULL
accepted	NULL
7/22/98	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

Supported	NULL
in	NULL
part	NULL
by	NULL
NIH	NULL
Grant	NULL
RO1-CA-56937	NULL
and	NULL
generous	NULL
gifts	NULL
from	NULL
the	NULL
Abbey	NULL
and	NULL
Nester	NULL
Martinez	NULL
Foundations	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
,	NULL
at	NULL
The	NULL
Cleveland	NULL
Clinic	NULL
Foundation	NULL
,	NULL
9500	NULL
Euclid	NULL
Avenue	NULL
,	NULL
Cleveland	NULL
,	NULL
OH	NULL
44195	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
216	NULL
)	NULL
444-6825	NULL
;	NULL
Fax	NULL
:	NULL
(	NULL
216	NULL
)	NULL
444-0114.	NULL
clonal	NULL
antibody	NULL
.	NULL

Changes	NULL
in	NULL
these	NULL
signaling	NULL
molecules	NULL
during	NULL
cytokine	NULL
treatment	NULL
were	NULL
also	NULL
investigated	NULL
.	NULL

TCR	NULL
and	NULL
p56	NULL
``	NULL
were	NULL
detected	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
in	NULL
27	NULL
of	NULL
29	NULL
patients	NULL
,	NULL
and	NULL
overall	NULL
,	NULL
reduced	NULL
levels	NULL
were	NULL
noted	NULL
visually	NULL
in	NULL
12	NULL
of	NULL
29	NULL
(	NULL
41	NULL
%	NULL
)	NULL
and	NULL
13	NULL
of	NULL
29	NULL
(	NULL
45	NULL
%	NULL
)	NULL
individuals	NULL
,	NULL
respectively	NULL
.	NULL

When	NULL
levels	NULL
were	NULL
semiquantitated	NULL
using	NULL
densitome-try	NULL
,	NULL
significant	NULL
decreases	NULL
of	NULL
TCR	NULL
(	NULL
P	NULL
=	NULL
0.029	NULL
)	NULL
and	NULL
p56	NULL
``	NULL
(	NULL
P	NULL
=	NULL
0.029	NULL
)	NULL
but	NULL
not	NULL
CD3e	NULL
(	NULL
P	NULL
=	NULL
0.131	NULL
)	NULL
,	NULL
compared	NULL
with	NULL
control	NULL
levels	NULL
,	NULL
were	NULL
found	NULL
.	NULL

In	NULL
patients	NULL
treated	NULL
with	NULL
IL-2/	NULL
IFNa-based	NULL
therapy	NULL
,	NULL
relative	NULL
levels	NULL
of	NULL
TCRL	NULL
increased	NULL
significantly	NULL
(	NULL
P	NULL
=	NULL
0.002	NULL
)	NULL
on	NULL
day	NULL
15	NULL
of	NULL
cycle	NULL
one	NULL
compared	NULL
with	NULL
the	NULL
baseline	NULL
.	NULL

Correlations	NULL
of	NULL
TCRC	NULL
or	NULL
p56	NULL
``	NULL
levels	NULL
with	NULL
response	NULL
or	NULL
disease	NULL
variables	NULL
,	NULL
except	NULL
for	NULL
lower	NULL
TCRL	NULL
levels	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
bone	NULL
metastases	NULL
,	NULL
were	NULL
not	NULL
found	NULL
.	NULL

Abnormal	NULL
NFB	NULL
activation	NULL
after	NULL
stimulation	NULL
with	NULL
phorbol	NULL
-	NULL
myristate	NULL
acetate/ionomycin	NULL
-	NULL
and/or	NULL
-	NULL
anti-CD3	NULL
monoclonal	NULL
antibody	NULL
was	NULL
found	NULL
in	NULL
59	NULL
%	NULL
of	NULL
patients	NULL
(	NULL
17	NULL
of	NULL
28	NULL
)	NULL
and	NULL
was	NULL
not	NULL
accounted	NULL
for	NULL
by	NULL
the	NULL
advanced	NULL
age	NULL
of	NULL
the	NULL
study	NULL
cohort	NULL
.	NULL

Activation	NULL
of	NULL
NFB	NULL
in	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
was	NULL
inducible	NULL
during	NULL
cytokine	NULL
therapy	NULL
in	NULL
four	NULL
of	NULL
six	NULL
individuals	NULL
who	NULL
displayed	NULL
impaired	NULL
NFB	NULL
activity	NULL
prior	NULL
to	NULL
therapy	NULL
.	NULL

Moreover	NULL
,	NULL
impaired	NULL
activation	NULL
of	NULL
NFB	NULL
does	NULL
not	NULL
appear	NULL
linked	NULL
to	NULL
a	NULL
reduction	NULL
of	NULL
TCR	NULL
expression	NULL
,	NULL
because	NULL
in	NULL
five	NULL
patients	NULL
,	NULL
normal	NULL
TCR	NULL
levels	NULL
were	NULL
present	NULL
although	NULL
B	NULL
binding	NULL
was	NULL
not	NULL
inducible	NULL
.	NULL

In	NULL
the	NULL
majority	NULL
of	NULL
patients	NULL
with	NULL
advanced	NULL
RCC	NULL
,	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
express	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
,	NULL
and	NULL
in	NULL
a	NULL
subset	NULL
,	NULL
reduced	NULL
levels	NULL
of	NULL
these	NULL
TCRL	NULL
associated	NULL
molecules	NULL
are	NULL
seen	NULL
that	NULL
may	NULL
increase	NULL
during	NULL
cytokine-based	NULL
therapy	NULL
.	NULL

Abnormal	NULL
activation	NULL
of	NULL
NFB	NULL
is	NULL
also	NULL
present	NULL
in	NULL
>	NULL
50	NULL
%	NULL
of	NULL
patients	NULL
and	NULL
may	NULL
also	NULL
revert	NULL
to	NULL
normal	NULL
during	NULL
IL-2/IFNa-based	NULL
treatment	NULL
.	NULL

This	NULL
alteration	NULL
in	NULL
NFB	NULL
activation	NULL
occurred	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
normal	NULL
expression	NULL
of	NULL
TCRG-associated	NULL
signaling	NULL
elements	NULL
.	NULL

The	NULL
clinical	NULL
significance	NULL
of	NULL
these	NULL
findings	NULL
remains	NULL
unclear	NULL
.	NULL

INTRODUCTION	NULL
Abnormalities	NULL
of	NULL
the	NULL
CD3/TCRÂ®	NULL
(	NULL
TCRL	NULL
)	NULL
and	NULL
signal	NULL
transduction	NULL
pathways	NULL
have	NULL
been	NULL
described	NULL
in	NULL
splenic	NULL
and	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
obtained	NULL
from	NULL
tumor-bearing	NULL
animals	NULL
(	NULL
1	NULL
)	NULL
and	NULL
patients	NULL
with	NULL
advanced	NULL
cancer	NULL
(	NULL
2	NULL
)	NULL
.	NULL

These	NULL
include	NULL
defects	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
TCR	NULL
chain	NULL
and	NULL
protein	NULL
tyrosine	NULL
ki-nases	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
p56	NULL
``	NULL
,	NULL
that	NULL
are	NULL
associated	NULL
with	NULL
the	NULL
TCRL	NULL
.	NULL

These	NULL
alterations	NULL
result	NULL
in	NULL
impaired	NULL
tyrosine	NULL
phosphorylation	NULL
after	NULL
li	NULL
*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
TCR	NULL
,	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
;	NULL
RCC	NULL
,	NULL
renal	NULL
cell	NULL
carcinoma	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
rIL	NULL
,	NULL
recombinant	NULL
IL	NULL
;	NULL
PBL-T	NULL
,	NULL
peripheral	NULL
blood	NULL
T	NULL
lymphocyte	NULL
;	NULL
PMSF	NULL
,	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
5-FU	NULL
,	NULL
5-fluorouracil	NULL
;	NULL
NF	NULL
,	NULL
nuclear	NULL
factor	NULL
.	NULL

Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

2338	NULL
Signal	NULL
Transduction	NULL
Abnormalities	NULL
in	NULL
T	NULL
Cells	NULL
Table	NULL
1	NULL
Treatment	NULL
regimens	NULL
administered	NULL
No	NULL
.	NULL

of	NULL
Regimen	NULL
Dose	NULL
(	NULL
s	NULL
)	NULL
Schedule	NULL
``	NULL
patients	NULL
-	NULL
Type	NULL
of	NULL
trial	NULL
Day	NULL
of	NULL
PBL	NULL
study	NULL
``	NULL
A	NULL
rIL-2/rHulFNa2b	NULL
rIL-2	NULL
9.0	NULL
MIU/mÂ®/day	NULL
_	NULL
CIV	NULL
di-5	NULL
,	NULL
8-12	NULL
,	NULL
15-19	NULL
,	NULL
22-26	NULL
4	NULL
Phase	NULL
II	NULL
Pre-	NULL
,	NULL
d8	NULL
to	NULL
429-56	NULL
rHuIFNaZb	NULL
10.0	NULL
MU/m*/day	NULL
SQ	NULL
TIW	NULL
B	NULL
rIL-2/rHulFNo2a	NULL
+	NULL
5-FU	NULL
rIL-2	NULL
5.0	NULL
mlU/m*Â®/day	NULL
__	NULL
SQ	NULL
dl-5	NULL
,	NULL
8-12	NULL
,	NULL
15-19	NULL
,	NULL
22-26	NULL
_	NULL
38Â°	NULL
Phase	NULL
UIL	NULL
__	NULL
Pre-	NULL
,	NULL
d8	NULL
,	NULL
and/or	NULL
d15	NULL
rHulFNa2a	NULL
5.0	NULL
mu/m*/day	NULL
SQ	NULL
TIW	NULL
SFU	NULL
0-350	NULL
mg/m*/day	NULL
LV.B	NULL
.	NULL

di-5	NULL
C	NULL
None	NULL
NA	NULL
NA	NULL
12	NULL
NA	NULL
Prior	NULL
to	NULL
surgery	NULL
or	NULL
therapy	NULL
for	NULL
metastatic	NULL
disease	NULL
D	NULL
None	NULL
NA	NULL
NA	NULL
11	NULL
Pilot	NULL
study	NULL
,	NULL
8	NULL
to	NULL
12	NULL
weeks	NULL
postnephrectomy	NULL
or	NULL
adjuvant	NULL
rIL-2	NULL
_	NULL
surgery	NULL
for	NULL
metastatic	NULL
disease	NULL
,	NULL
prior	NULL
to	NULL
cytokine	NULL
administration	NULL
``	NULL
CIV	NULL
,	NULL
continuous	NULL
intravenous	NULL
;	NULL
dl-5	NULL
,	NULL
days	NULL
1-5	NULL
,	NULL
etc	NULL
.	NULL

,	NULL
SQ	NULL
,	NULL
subcutaneous	NULL
;	NULL
TIW	NULL
,	NULL
three	NULL
times	NULL
weekly	NULL
;	NULL
I.V.B	NULL
.	NULL

,	NULL
intravenous	NULL
bolus	NULL
;	NULL
NA	NULL
,	NULL
not	NULL
applicable	NULL
.	NULL

*	NULL
48	NULL
,	NULL
day	NULL
8	NULL
;	NULL
d15	NULL
,	NULL
day	NULL
15	NULL
.	NULL

Â©	NULL
Three	NULL
patients	NULL
received	NULL
rIL-2/IFNa2a	NULL
only	NULL
,	NULL
without	NULL
5-FU	NULL
.	NULL

gation	NULL
of	NULL
the	NULL
CD3	NULL
complex	NULL
.	NULL

Although	NULL
less	NULL
frequent	NULL
,	NULL
similar	NULL
findings	NULL
in	NULL
peripheral	NULL
blood	NULL
T-cells	NULL
from	NULL
melanoma	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
,	NULL
RCC	NULL
(	NULL
2	NULL
,	NULL
5	NULL
)	NULL
,	NULL
ovarian	NULL
carcinoma	NULL
(	NULL
6	NULL
)	NULL
,	NULL
Hodgkin	NULL
's	NULL
disease	NULL
(	NULL
7	NULL
)	NULL
,	NULL
and	NULL
colorectal	NULL
cancer	NULL
(	NULL
8	NULL
)	NULL
patients	NULL
have	NULL
also	NULL
been	NULL
reported	NULL
and	NULL
in	NULL
the	NULL
last	NULL
instance	NULL
may	NULL
be	NULL
correlated	NULL
with	NULL
disease	NULL
stage	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
and	NULL
others	NULL
have	NULL
reported	NULL
that	NULL
T	NULL
cells	NULL
from	NULL
tumor-bearing	NULL
animals	NULL
(	NULL
10	NULL
)	NULL
and	NULL
RCC	NULL
patients	NULL
(	NULL
11	NULL
)	NULL
also	NULL
have	NULL
reduced	NULL
6B	NULL
sequence	NULL
motif-specific	NULL
binding	NULL
activity	NULL
.	NULL

The	NULL
major	NULL
alteration	NULL
appears	NULL
to	NULL
be	NULL
in	NULL
the	NULL
nuclear	NULL
localization	NULL
of	NULL
Rel	NULL
A	NULL
containing	NULL
NFKB	NULL
complexes	NULL
after	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Altered	NULL
expression	NULL
of	NULL
various	NULL
signal	NULL
transduction	NULL
molecules	NULL
may	NULL
be	NULL
associated	NULL
with	NULL
functional	NULL
defects	NULL
noted	NULL
in	NULL
T	NULL
cells	NULL
isolated	NULL
from	NULL
tumor-bearing	NULL
hosts	NULL
(	NULL
4	NULL
)	NULL
and	NULL
may	NULL
be	NULL
a	NULL
contributing	NULL
factor	NULL
responsible	NULL
for	NULL
the	NULL
inability	NULL
to	NULL
develop	NULL
an	NULL
effective	NULL
antitumor	NULL
immune	NULL
response	NULL
.	NULL

Defects	NULL
in	NULL
proliferation	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
,	NULL
lytic	NULL
capacity	NULL
(	NULL
12	NULL
)	NULL
,	NULL
and	NULL
cytokine	NULL
secretion	NULL
(	NULL
14	NULL
)	NULL
have	NULL
been	NULL
described	NULL
for	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
various	NULL
types	NULL
of	NULL
solid	NULL
tumors	NULL
.	NULL

In	NULL
mice	NULL
with	NULL
transplantable	NULL
neo-plasms	NULL
(	NULL
RENCA	NULL
and	NULL
MCA-38	NULL
)	NULL
,	NULL
tumor	NULL
progression	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
reduction	NULL
in	NULL
expression	NULL
of	NULL
signaling	NULL
elements	NULL
and	NULL
a	NULL
decrease	NULL
in	NULL
production	NULL
of	NULL
the	NULL
TH1	NULL
cytokines	NULL
IL-2	NULL
and	NULL
IFNy	NULL
by	NULL
splenic	NULL
T	NULL
cells	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
in	NULL
patients	NULL
with	NULL
metastatic	NULL
melanoma	NULL
,	NULL
whose	NULL
T	NULL
cells	NULL
displayed	NULL
reduced	NULL
TCRL	NULL
expression	NULL
,	NULL
diminished	NULL
production	NULL
of	NULL
IL-2	NULL
and	NULL
IFNy	NULL
(	NULL
4	NULL
)	NULL
has	NULL
been	NULL
observed	NULL
.	NULL

Moreover	NULL
,	NULL
studies	NULL
in	NULL
animals	NULL
suggest	NULL
that	NULL
cytokine-based	NULL
Im-munotherapy	NULL
may	NULL
result	NULL
in	NULL
the	NULL
reversal	NULL
of	NULL
some	NULL
signaling	NULL
defects	NULL
(	NULL
15	NULL
)	NULL
.	NULL

RCC	NULL
represents	NULL
a	NULL
tumor	NULL
in	NULL
which	NULL
cytokine	NULL
therapy	NULL
is	NULL
used	NULL
frequently	NULL
;	NULL
however	NULL
,	NULL
the	NULL
clinical	NULL
significance	NULL
of	NULL
the	NULL
observed	NULL
signaling	NULL
abnormalities	NULL
and	NULL
the	NULL
effects	NULL
of	NULL
cytokine	NULL
therapy	NULL
on	NULL
these	NULL
findings	NULL
are	NULL
unclear	NULL
.	NULL

The	NULL
present	NULL
study	NULL
was	NULL
therefore	NULL
initiated	NULL
to	NULL
further	NULL
characterize	NULL
the	NULL
frequency	NULL
of	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
abnormalities	NULL
in	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
RCC	NULL
,	NULL
correlate	NULL
these	NULL
abnormalities	NULL
with	NULL
clinical	NULL
character-istics	NULL
,	NULL
and	NULL
investigate	NULL
alterations	NULL
occurring	NULL
during	NULL
cytokine	NULL
therapy	NULL
.	NULL

Additionally	NULL
in	NULL
view	NULL
of	NULL
recent	NULL
findings	NULL
cited	NULL
previously	NULL
,	NULL
the	NULL
frequency	NULL
of	NULL
abnormal	NULL
NFkB	NULL
activation	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
was	NULL
studied	NULL
.	NULL

The	NULL
results	NULL
demonstrate	NULL
reduced	NULL
expression	NULL
of	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
a	NULL
subset	NULL
of	NULL
patients	NULL
with	NULL
advanced	NULL
RCC	NULL
and	NULL
possible	NULL
increases	NULL
in	NULL
TCRL	NULL
expression	NULL
during	NULL
therapy	NULL
with	NULL
rIL-2-	NULL
and	NULL
IFNa-containing	NULL
regimens	NULL
.	NULL

Abnor-	NULL
mal	NULL
activation	NULL
of	NULL
NFkB	NULL
was	NULL
also	NULL
found	NULL
in	NULL
59	NULL
%	NULL
of	NULL
patients	NULL
,	NULL
which	NULL
reverted	NULL
to	NULL
a	NULL
normal	NULL
pattern	NULL
in	NULL
some	NULL
individuals	NULL
during	NULL
cytokine	NULL
therapy	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
alterations	NULL
in	NULL
signal	NULL
transduction	NULL
that	NULL
are	NULL
associated	NULL
with	NULL
defective	NULL
NFKB	NULL
activation	NULL
are	NULL
distinct	NULL
and	NULL
downstream	NULL
from	NULL
early	NULL
CD3/TCR-linked	NULL
signaling	NULL
events	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Patient	NULL
Selection	NULL
.	NULL

-	NULL
Patients	NULL
with	NULL
metastatic	NULL
and/or	NULL
recurrent	NULL
renal	NULL
cell	NULL
carcinoma	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
whom	NULL
were	NULL
treated	NULL
in	NULL
a	NULL
series	NULL
of	NULL
Phase	NULL
I	NULL
or	NULL
II	NULL
clinical	NULL
trials	NULL
,	NULL
were	NULL
studied	NULL
.	NULL

A	NULL
total	NULL
of	NULL
65	NULL
patients	NULL
were	NULL
investigated	NULL
.	NULL

The	NULL
treatment	NULL
regimens	NULL
administered	NULL
to	NULL
the	NULL
various	NULL
groups	NULL
are	NULL
outlined	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Peripheral	NULL
blood	NULL
was	NULL
sampled	NULL
pretherapy	NULL
and	NULL
at	NULL
various	NULL
time	NULL
points	NULL
during	NULL
and	NULL
after	NULL
treatment	NULL
(	NULL
see	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Informed	NULL
consent	NULL
was	NULL
obtained	NULL
in	NULL
accordance	NULL
with	NULL
institutional	NULL
and	NULL
National	NULL
Cancer	NULL
Institute	NULL
guidelines	NULL
.	NULL

Control	NULL
Subjects	NULL
.	NULL

Peripheral	NULL
blood	NULL
T	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
37	NULL
healthy	NULL
donors	NULL
to	NULL
serve	NULL
as	NULL
controls	NULL
.	NULL

In	NULL
studies	NULL
using	NULL
Western	NULL
blotting	NULL
,	NULL
whole-cell	NULL
lysate	NULL
from	NULL
the	NULL
same	NULL
healthy	NULL
donor	NULL
was	NULL
included	NULL
in	NULL
each	NULL
experiment	NULL
when	NULL
TCRL	NULL
,	NULL
CD3e	NULL
,	NULL
and	NULL
p56	NULL
``	NULL
from	NULL
patient	NULL
T	NULL
cells	NULL
were	NULL
analyzed	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
variation	NULL
in	NULL
signaling	NULL
element	NULL
expression	NULL
among	NULL
individuals	NULL
,	NULL
cell	NULL
lysates	NULL
from	NULL
five	NULL
healthy	NULL
donors	NULL
were	NULL
run	NULL
in	NULL
the	NULL
same	NULL
experiment	NULL
.	NULL

To	NULL
assess	NULL
variations	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
TCRL	NULL
,	NULL
p56'*	NULL
,	NULL
and	NULL
CD3e	NULL
over	NULL
time	NULL
,	NULL
these	NULL
signaling	NULL
elements	NULL
were	NULL
measured	NULL
in	NULL
three	NULL
additional	NULL
normal	NULL
donors	NULL
at	NULL
three	NULL
separate	NULL
time	NULL
points	NULL
.	NULL

T-cell	NULL
nuclear	NULL
lysates	NULL
from	NULL
20	NULL
different	NULL
healthy	NULL
individuals	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
when	NULL
NFxB	NULL
activation	NULL
was	NULL
evaluated	NULL
in	NULL
patient	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
T	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
redundant	NULL
leukophore-sis	NULL
samples	NULL
(	NULL
Cleveland	NULL
Clinic	NULL
Blood	NULL
Bank	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
level	NULL
of	NULL
stimulus-dependent	NULL
6B	NULL
binding	NULL
activity	NULL
from	NULL
RCC	NULL
patient	NULL
T	NULL
cells	NULL
was	NULL
compared	NULL
with	NULL
an	NULL
age-matched	NULL
control	NULL
group	NULL
(	NULL
n	NULL
=	NULL
8	NULL
)	NULL
.	NULL

Isolation	NULL
of	NULL
PBL-T.	NULL
PBLs	NULL
were	NULL
isolated	NULL
,	NULL
and	NULL
PBL-Ts	NULL
were	NULL
purified	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
2	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
PBLs	NULL
were	NULL
subjected	NULL
to	NULL
Ficoll-Hypaque	NULL
(	NULL
LKD	NULL
Biotech	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
density	NULL
gradient	NULL
centrifugation	NULL
and	NULL
depleted	NULL
of	NULL
B	NULL
celis	NULL
,	NULL
natural	NULL
killer	NULL
cells	NULL
,	NULL
and	NULL
macrophages	NULL
by	NULL
negative	NULL
selection	NULL
using	NULL
magnetic	NULL
separation	NULL
with	NULL
microbeads	NULL
coated	NULL
with	NULL
antibodies	NULL
to	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

Clinical	NULL
Cancer	NULL
Research	NULL
2339	NULL
Pt	NULL
.	NULL

SF	NULL
+	NULL
Pt	NULL
.	NULL

DI	NULL
+	NULL
Pt	NULL
.	NULL

WA	NULL
+	NULL
-	NULL
+	NULL
rss	NULL
#	NULL
#	NULL
_	NULL
dik	NULL
H	NULL
#	NULL
4	NULL
am	NULL
_	NULL
Â«	NULL
wit	NULL
<	NULL
A	NULL
CD3e	NULL
Q	NULL
m	NULL
amt	NULL
am	NULL
&	NULL
-	NULL
aP	NULL
came	NULL
ap	NULL
-	NULL
3000	NULL
3000	NULL
3000	NULL
3000	NULL
E	NULL
2	NULL
2000	NULL
2000	NULL
2000	NULL
2000	NULL
Â©	NULL
P3	NULL
Â®	NULL
1000	NULL
I	NULL
l	NULL
1000	NULL
1000	NULL
1000	NULL
0	NULL
0	NULL
l	NULL
o	NULL
o	NULL
pS6K	NULL
TCR	NULL
CD3e	NULL
TCRC	NULL
CD32	NULL
p56kK	NULL
TCR	NULL
CD3e	NULL
pS6kK	NULL
TCR	NULL
CD3e	NULL
Fig	NULL
.	NULL

1	NULL
-	NULL
Western	NULL
blots	NULL
demonstrating	NULL
levels	NULL
of	NULL
TCR4	NULL
,	NULL
pS6	NULL
``	NULL
**	NULL
,	NULL
and	NULL
CD3e	NULL
in	NULL
four	NULL
patients	NULL
compared	NULL
with	NULL
a	NULL
control	NULL
individual	NULL
(	NULL
+	NULL
)	NULL
.	NULL

Corresponding	NULL
densitometry	NULL
data	NULL
are	NULL
included	NULL
illustrating	NULL
the	NULL
differences	NULL
between	NULL
patients	NULL
and	NULL
controls	NULL
(	NULL
BBB	NULL
,	NULL
patient	NULL
;	NULL
I	NULL
,	NULL
control	NULL
)	NULL
.	NULL

Representative	NULL
data	NULL
illustrate	NULL
various	NULL
patterns	NULL
in	NULL
which	NULL
T	NULL
cells	NULL
from	NULL
one	NULL
patient	NULL
(	NULL
S.	NULL
F.	NULL
;	NULL
Pr	NULL
.	NULL

SF	NULL
)	NULL
display	NULL
normal	NULL
levels	NULL
of	NULL
signaling	NULL
elements	NULL
,	NULL
those	NULL
from	NULL
two	NULL
patients	NULL
(	NULL
D.	NULL
I.	NULL
and	NULL
W.	NULL
A.	NULL
;	NULL
Pr	NULL
.	NULL

DI	NULL
and	NULL
Pt	NULL
.	NULL

WA	NULL
,	NULL
respectively	NULL
)	NULL
display	NULL
reduced	NULL
levels	NULL
of	NULL
TCR4L	NULL
,	NULL
and	NULL
those	NULL
from	NULL
one	NULL
patient	NULL
(	NULL
D.	NULL
G.	NULL
;	NULL
Pr	NULL
.	NULL

DG	NULL
)	NULL
,	NULL
which	NULL
display	NULL
no	NULL
detectable	NULL
levels	NULL
of	NULL
TCRL	NULL
and	NULL
p56'Â®	NULL
.	NULL

CD19	NULL
,	NULL
CD16	NULL
,	NULL
and	NULL
CD14	NULL
(	NULL
Milteny	NULL
Biotec	NULL
,	NULL
Inc.	NULL
,	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
populations	NULL
isolated	NULL
(	NULL
PBL-T	NULL
)	NULL
contained	NULL
>	NULL
90	NULL
%	NULL
cells	NULL
positive	NULL
for	NULL
CD3	NULL
as	NULL
determined	NULL
by	NULL
immunostaining	NULL
.	NULL

Western	NULL
Blot	NULL
.	NULL

-	NULL
PBL-Ts	NULL
were	NULL
lysed	NULL
by	NULL
incubation	NULL
in	NULL
lysis	NULL
buffer	NULL
[	NULL
PBS	NULL
(	NULL
calcium	NULL
and	NULL
magnesium	NULL
free	NULL
)	NULL
,	NULL
10	NULL
mm	NULL
sodium	NULL
phosphate	NULL
,	NULL
20	NULL
mm	NULL
HEPES	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
100	NULL
mm	NULL
NaCl	NULL
,	NULL
1	NULL
mm	NULL
ZnCl	NULL
,	NULL
1	NULL
mg/ml	NULL
NaF	NULL
,	NULL
100	NULL
pg/ml	NULL
PMSF	NULL
,	NULL
200	NULL
pg/ml	NULL
!	NULL

chymo-statin	NULL
,	NULL
100	NULL
pg/ml	NULL
Pefabloc	NULL
,	NULL
and	NULL
200	NULL
g/m	NULL
!	NULL

trypsin/chymotryp-sin	NULL
inhibitor	NULL
,	NULL
1	NULL
mm	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
2	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
and	NULL
2	NULL
pg/ml	NULL
leupeptin	NULL
]	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4Â°C	NULL
.	NULL

The	NULL
lysate	NULL
was	NULL
centrifuged	NULL
at	NULL
12,000	NULL
rpm	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4Â°C	NULL
,	NULL
after	NULL
which	NULL
the	NULL
supernatant	NULL
was	NULL
carefully	NULL
harvested	NULL
to	NULL
not	NULL
disturb	NULL
the	NULL
pellet	NULL
.	NULL

Cellular	NULL
lysates	NULL
(	NULL
10-20	NULL
pg	NULL
of	NULL
equivalent	NULL
loading	NULL
in	NULL
each	NULL
one	NULL
)	NULL
were	NULL
electrophoresed	NULL
in	NULL
12	NULL
%	NULL
(	NULL
for	NULL
TCRL	NULL
)	NULL
or	NULL
7.5	NULL
%	NULL
(	NULL
for	NULL
p56	NULL
``	NULL
)	NULL
SDS	NULL
page	NULL
under	NULL
reducing	NULL
conditions	NULL
and	NULL
then	NULL
transferred	NULL
to	NULL
NitroBind	NULL
(	NULL
Nitrocellulose	NULL
)	NULL
transfer	NULL
membranes	NULL
(	NULL
MSI	NULL
,	NULL
Westboro	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
incubated	NULL
overnight	NULL
at	NULL
4Â°C	NULL
with	NULL
a	NULL
5	NULL
%	NULL
solution	NULL
of	NULL
nonfat	NULL
dried	NULL
milk	NULL
.	NULL

Then	NULL
the	NULL
membranes	NULL
were	NULL
blotted	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
anti-TCRE	NULL
antibody	NULL
(	NULL
Coulter	NULL
Corp.	NULL
,	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
at	NULL
5	NULL
pg/ml	NULL
,	NULL
anti-p56	NULL
``	NULL
``	NULL
``	NULL
(	NULL
Upstate	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
at	NULL
1	NULL
pg/ml	NULL
,	NULL
and	NULL
anti-CD3e	NULL
(	NULL
DAKO	NULL
Co.	NULL
,	NULL
Carpinteria	NULL
,	NULL
CA	NULL
)	NULL
at	NULL
5	NULL
pg/ml	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
washed	NULL
with	NULL
1	NULL
mM	NULL
Tris	NULL
base	NULL
,	NULL
5	NULL
m	NULL
NaCl	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
and	NULL
incubated	NULL
with	NULL
anti-rabbit	NULL
or	NULL
anti-mouse	NULL
immunoglobulin	NULL
horseradish	NULL
peroxidase	NULL
diluted	NULL
1:2000	NULL
(	NULL
Amer-sham	NULL
,	NULL
Buckinghamshire	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
.	NULL

After	NULL
washing	NULL
with	NULL
1	NULL
m	NULL
Tris	NULL
base	NULL
,	NULL
5	NULL
m	NULL
NaCl	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
the	NULL
membranes	NULL
were	NULL
developed	NULL
with	NULL
the	NULL
chemiluminescence	NULL
kit	NULL
ECL	NULL
(	NULL
Amersham	NULL
)	NULL
for	NULL
1	NULL
min	NULL
.	NULL

X-Omat	NULL
AR	NULL
film	NULL
(	NULL
Kodak	NULL
Co.	NULL
,	NULL
Rochester	NULL
NY	NULL
)	NULL
was	NULL
used	NULL
to	NULL
detect	NULL
the	NULL
chemiluminescence	NULL
.	NULL

Patient	NULL
samples	NULL
and	NULL
the	NULL
same	NULL
normal	NULL
control	NULL
were	NULL
included	NULL
on	NULL
each	NULL
Western	NULL
blot	NULL
.	NULL

All	NULL
samples	NULL
for	NULL
a	NULL
given	NULL
patient	NULL
were	NULL
run	NULL
in	NULL
the	NULL
same	NULL
Western	NULL
blots	NULL
so	NULL
that	NULL
comparisons	NULL
between	NULL
pretreatment	NULL
and	NULL
treatment	NULL
samples	NULL
could	NULL
be	NULL
made	NULL
.	NULL

Densitometry	NULL
Scanning	NULL
.	NULL

The	NULL
developed	NULL
X-omat	NULL
AR	NULL
Film	NULL
was	NULL
placed	NULL
on	NULL
a	NULL
white	NULL
light	NULL
box	NULL
(	NULL
Vari	NULL
Quest	NULL
100	NULL
)	NULL
by	NULL
Fotodyn	NULL
,	NULL
and	NULL
its	NULL
images	NULL
were	NULL
captured	NULL
by	NULL
a	NULL
High	NULL
Resolution	NULL
CCD	NULL
Camera	NULL
(	NULL
Sierra	NULL
Scientific	NULL
)	NULL
.	NULL

Image	NULL
1.44	NULL
was	NULL
the	NULL
program	NULL
used	NULL
to	NULL
analyze	NULL
the	NULL
density	NULL
of	NULL
each	NULL
band	NULL
by	NULL
graphically	NULL
plotting	NULL
the	NULL
images	NULL
and	NULL
calculating	NULL
the	NULL
area	NULL
under	NULL
each	NULL
peak	NULL
.	NULL

NFB	NULL
-	NULL
Activation/T-Lymphocyte	NULL
-	NULL
Culture	NULL
.	NULL

PBL-Ts	NULL
(	NULL
1	NULL
X	NULL
10	NULL
%	NULL
/ml	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
stimulus	NULL
.	NULL

The	NULL
medium	NULL
was	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
2	NULL
%	NULL
FCS	NULL
.	NULL

T	NULL
Cells	NULL
were	NULL
stimulated	NULL
with	NULL
10	NULL
ng/ml	NULL
of	NULL
PMA	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
plus	NULL
0.75	NULL
pg/ml	NULL
ionomycin	NULL
(	NULL
Sigma	NULL
)	NULL
for	NULL
0.25	NULL
,	NULL
0.5	NULL
,	NULL
2	NULL
,	NULL
and	NULL
4	NULL
h.	NULL
In	NULL
some	NULL
experiments	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
cross-linked	NULL
anti-CD3	NULL
monoclonal	NULL
antibody	NULL
(	NULL
Ortho	NULL
Biotech	NULL
,	NULL
Raritan	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

EMSA	NULL
.	NULL

-	NULL
Cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
Schreiber	NULL
et	NULL
al	NULL
.	NULL

(	NULL
16	NULL
)	NULL
with	NULL
minor	NULL
modifications	NULL
.	NULL

Briefly	NULL
,	NULL
PBL-T	NULL
(	NULL
10	NULL
)	NULL
were	NULL
harvested	NULL
and	NULL
washed	NULL
with	NULL
cold	NULL
PBS	NULL
and	NULL
then	NULL
sedimented	NULL
by	NULL
centrifugation	NULL
at	NULL
1500	NULL
rpm	NULL
for	NULL
5	NULL
min	NULL
.	NULL

The	NULL
cell	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
150	NULL
pl	NULL
of	NULL
buffer	NULL
A	NULL
[	NULL
10	NULL
mm	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
10	NULL
mm	NULL
KCI	NULL
,	NULL
0.1	NULL
mm	NULL
EDTA	NULL
,	NULL
0.1	NULL
mm	NULL
EGTA	NULL
,	NULL
1	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

2340	NULL
Signal	NULL
Transduction	NULL
Abnormalities	NULL
in	NULL
T	NULL
Cells	NULL
Normals	NULL
MH	NULL
DP	NULL
JS	NULL
Day	NULL
0	NULL
8	NULL
150	NULL
0	NULL
8	NULL
150	NULL
0	NULL
8	NULL
15	NULL
Fig	NULL
.	NULL

2	NULL
Western	NULL
blots	NULL
demonstrating	NULL
levels	NULL
of	NULL
TCRL	NULL
,	NULL
p56	NULL
``	NULL
,	NULL
and	NULL
CD3e	NULL
in	NULL
three	NULL
normal	NULL
individuals	NULL
who	NULL
were	NULL
studied	NULL
on	NULL
days	NULL
0	NULL
,	NULL
8	NULL
,	NULL
and	NULL
15	NULL
.	NULL

Minimal	NULL
variation	NULL
in	NULL
levels	NULL
of	NULL
signaling	NULL
molecules	NULL
within	NULL
a	NULL
single	NULL
person	NULL
at	NULL
different	NULL
time	NULL
points	NULL
and	NULL
variation	NULL
between	NULL
the	NULL
different	NULL
individuals	NULL
are	NULL
illustrated	NULL
.	NULL

mM	NULL
DTT	NULL
,	NULL
100	NULL
pg/ml	NULL
PMSF	NULL
,	NULL
2	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
2	NULL
pg/ml	NULL
leupeptin	NULL
,	NULL
100	NULL
mg/ml	NULL
Pefabloc	NULL
,	NULL
and	NULL
0.1	NULL
pg/ml	NULL
chymostatin	NULL
]	NULL
by	NULL
gentle	NULL
pipetting	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
15	NULL
min	NULL
and	NULL
then	NULL
10	NULL
pl	NULL
of	NULL
10	NULL
%	NULL
NP4O0	NULL
solution	NULL
(	NULL
Sigma	NULL
)	NULL
were	NULL
added	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
vigorously	NULL
mixed	NULL
for	NULL
10	NULL
s	NULL
and	NULL
then	NULL
centrifuged	NULL
.	NULL

The	NULL
supernatant	NULL
containing	NULL
cytoplasmic	NULL
proteins	NULL
was	NULL
transferred	NULL
to	NULL
another	NULL
tube	NULL
and	NULL
aliquoted	NULL
.	NULL

Nuclei	NULL
were	NULL
resuspended	NULL
in	NULL
50	NULL
pl	NULL
of	NULL
buffer	NULL
C	NULL
[	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
20	NULL
mm	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
0.4	NULL
m	NULL
NaCl	NULL
,	NULL
1	NULL
mm	NULL
EDTA	NULL
,	NULL
1	NULL
mm	NULL
EGTA	NULL
,	NULL
1	NULL
mm	NULL
DTT	NULL
,	NULL
100	NULL
pg/ml	NULL
PMSF	NULL
,	NULL
2	NULL
g/ml	NULL
aprotinin	NULL
,	NULL
2	NULL
pg/ml	NULL
leupeptin	NULL
,	NULL
100	NULL
pg/ml	NULL
Pefabloc	NULL
,	NULL
and	NULL
100	NULL
pg/ml	NULL
chymostatin	NULL
]	NULL
.	NULL

After	NULL
mixing	NULL
at	NULL
4Â°C	NULL
for	NULL
20	NULL
min	NULL
,	NULL
the	NULL
nuclei	NULL
were	NULL
centrifuged	NULL
for	NULL
10	NULL
min	NULL
at	NULL
13,200	NULL
rpm	NULL
,	NULL
and	NULL
supernatants	NULL
containing	NULL
the	NULL
nuclear	NULL
proteins	NULL
were	NULL
stored	NULL
at	NULL
-70Â°C	NULL
.	NULL

Protein	NULL
concentration	NULL
was	NULL
measured	NULL
with	NULL
a	NULL
commercial	NULL
kit	NULL
(	NULL
Pierce	NULL
BCA	NULL
kit	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
as	NULL
specified	NULL
by	NULL
the	NULL
manufac-turer	NULL
.	NULL

As	NULL
described	NULL
previously	NULL
(	NULL
10	NULL
,	NULL
17	NULL
)	NULL
,	NULL
nuclear	NULL
extracts	NULL
(	NULL
5	NULL
ug	NULL
of	NULL
protein	NULL
)	NULL
were	NULL
preincubated	NULL
in	NULL
a	NULL
25-pl	NULL
total	NULL
reaction	NULL
volume	NULL
containing	NULL
20	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
80	NULL
mm	NULL
NaCl	NULL
,	NULL
0.1	NULL
mm	NULL
EDTA	NULL
,	NULL
1	NULL
mm	NULL
DTT	NULL
,	NULL
8	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
2	NULL
pl	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4Â°C	NULL
.	NULL

The	NULL
reaction	NULL
mixture	NULL
was	NULL
then	NULL
incubated	NULL
with	NULL
the	NULL
radiolabeled	NULL
oligonucleotide	NULL
(	NULL
2	NULL
X	NULL
10Â°	NULL
cpm	NULL
)	NULL
for	NULL
20	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
analyzed	NULL
by	NULL
electrophoresis	NULL
in	NULL
a	NULL
6	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gel	NULL
with	NULL
0.25	NULL
%	NULL
TBE	NULL
buffer	NULL
(	NULL
22.3	NULL
mm	NULL
Tris	NULL
,	NULL
22.2	NULL
mm	NULL
boric	NULL
acid	NULL
,	NULL
and	NULL
0.5	NULL
mm	NULL
EDTA	NULL
)	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
analyzed	NULL
by	NULL
autoradiography	NULL
.	NULL

For	NULL
the	NULL
preparation	NULL
of	NULL
the	NULL
probe	NULL
,	NULL
radiolabeled	NULL
double-stranded	NULL
oligonucleotides	NULL
were	NULL
prepared	NULL
by	NULL
annealing	NULL
coding	NULL
strand	NULL
template	NULL
to	NULL
a	NULL
complementary	NULL
10-base	NULL
primer	NULL
and	NULL
filling	NULL
in	NULL
the	NULL
overhang	NULL
with	NULL
the	NULL
Klenow	NULL
fragment	NULL
of	NULL
DNA	NULL
polymerase	NULL
I	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
a	NULL
Â«	NULL
-	NULL
``	NULL
Â°P	NULL
]	NULL
dCTP	NULL
.	NULL

Oligonucleotide	NULL
corresponding	NULL
to	NULL
6B	NULL
element	NULL
from	NULL
IL-2Ra	NULL
gene	NULL
was	NULL
prepared	NULL
by	NULL
using	NULL
an	NULL
Applied	NULL
Biosystems	NULL
oligonucleotide	NULL
synthesizer	NULL
(	NULL
model	NULL
381	NULL
A	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
oligonucleotide	NULL
was	NULL
:	NULL
5-CAACGGCAGG-GGAATCTCCCTCTCCTT-3	NULL
'	NULL
.	NULL

Supershift	NULL
experiments	NULL
were	NULL
performed	NULL
using	NULL
standard	NULL
EMSA	NULL
procedure	NULL
described	NULL
previously	NULL
,	NULL
with	NULL
the	NULL
exception	NULL
that	NULL
25	NULL
ul	NULL
of	NULL
reaction	NULL
mixture	NULL
were	NULL
preincubated	NULL
with	NULL
2	NULL
wl/2	NULL
ug	NULL
of	NULL
the	NULL
appropriate	NULL
antibody	NULL
at	NULL
4Â°C	NULL
for	NULL
15	NULL
min	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
labeled	NULL
oligonucleotide	NULL
.	NULL

Thereafter	NULL
,	NULL
the	NULL
samples	NULL
were	NULL
electrophoresed	NULL
in	NULL
a	NULL
6	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

The	NULL
antibodies	NULL
used	NULL
included	NULL
;	NULL
anti-NFkB1	NULL
,	NULL
anti-RelA	NULL
,	NULL
and	NULL
anti-c-Rel	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Normal	NULL
rabbit	NULL
serum	NULL
2	NULL
pl	NULL
(	NULL
2	NULL
g	NULL
;	NULL
Jackson	NULL
Immuno	NULL
Research	NULL
Laboratory	NULL
,	NULL
West	NULL
Grove	NULL
,	NULL
PA	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
.	NULL

Statistical	NULL
Analysis	NULL
.	NULL

Relative	NULL
levels	NULL
of	NULL
TCRL	NULL
,	NULL
p56	NULL
``	NULL
Â®	NULL
,	NULL
and	NULL
CD3e	NULL
were	NULL
determined	NULL
by	NULL
densitometry	NULL
scanning	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
variability	NULL
between	NULL
Western	NULL
blots	NULL
performed	NULL
at	NULL
different	NULL
times	NULL
,	NULL
direct	NULL
comparisons	NULL
could	NULL
not	NULL
be	NULL
made	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
ratios	NULL
of	NULL
control	NULL
and	NULL
pretreatment	NULL
values	NULL
were	NULL
used	NULL
.	NULL

These	NULL
values	NULL
were	NULL
used	NULL
to	NULL
compute	NULL
summary	NULL
statistics	NULL
and	NULL
Ps	NULL
for	NULL
various	NULL
patient	NULL
groups	NULL
.	NULL

The	NULL
Wilcoxon	NULL
signed	NULL
rank	NULL
test	NULL
(	NULL
two-sided	NULL
;	NULL
Ref	NULL
.	NULL

18	NULL
)	NULL
was	NULL
used	NULL
to	NULL
test	NULL
for	NULL
a	NULL
difference	NULL
between	NULL
the	NULL
control	NULL
and	NULL
pretreatment	NULL
values	NULL
after	NULL
computing	NULL
the	NULL
following	NULL
:	NULL
Patient	NULL
value	NULL
,	NULL
,	NULL
Control	NULL
value	NULL
To	NULL
determine	NULL
changes	NULL
associated	NULL
with	NULL
treatment	NULL
,	NULL
the	NULL
following	NULL
value	NULL
was	NULL
calculated	NULL
using	NULL
control	NULL
and	NULL
patient	NULL
signaling	NULL
molecule	NULL
levels	NULL
on	NULL
either	NULL
day	NULL
8	NULL
or	NULL
15	NULL
:	NULL
Patient	NULL
valueps	NULL
,	NULL
,	NULL
is	NULL
-	NULL
Patient	NULL
value	NULL
,	NULL
,	NULL
Control	NULL
value	NULL
The	NULL
Wilcoxon	NULL
rank	NULL
sum	NULL
(	NULL
two-sided	NULL
)	NULL
test	NULL
(	NULL
18	NULL
)	NULL
was	NULL
used	NULL
to	NULL
test	NULL
for	NULL
a	NULL
difference	NULL
between	NULL
responders	NULL
and	NULL
nonresponders	NULL
using	NULL
the	NULL
ratios	NULL
of	NULL
pretreatment	NULL
to	NULL
control	NULL
values	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
relationships	NULL
between	NULL
patient	NULL
clinical	NULL
characteristics	NULL
and	NULL
levels	NULL
of	NULL
signaling	NULL
molecules	NULL
,	NULL
a	NULL
multiple	NULL
linear	NULL
regression	NULL
model	NULL
(	NULL
19	NULL
)	NULL
was	NULL
fit	NULL
to	NULL
the	NULL
logarithm	NULL
of	NULL
the	NULL
ratio	NULL
of	NULL
the	NULL
pretreatment	NULL
value	NULL
over	NULL
the	NULL
control	NULL
value	NULL
for	NULL
p56	NULL
``	NULL
,	NULL
TCR	NULL
,	NULL
and	NULL
CD3e	NULL
.	NULL

The	NULL
common	NULL
logarithm	NULL
was	NULL
computed	NULL
in	NULL
an	NULL
attempt	NULL
to	NULL
stabilize	NULL
variances	NULL
;	NULL
one	NULL
was	NULL
added	NULL
to	NULL
the	NULL
pretreatment	NULL
values	NULL
to	NULL
avoid	NULL
taking	NULL
the	NULL
logarithm	NULL
of	NULL
zero	NULL
.	NULL

Factors	NULL
were	NULL
eliminated	NULL
in	NULL
a	NULL
backward	NULL
fashion	NULL
and	NULL
consisted	NULL
of	NULL
age	NULL
,	NULL
prior	NULL
therapy	NULL
,	NULL
gender	NULL
,	NULL
performance	NULL
status	NULL
,	NULL
primary	NULL
tumor	NULL
in	NULL
place	NULL
,	NULL
individual	NULL
metastatic	NULL
sites	NULL
of	NULL
lung	NULL
,	NULL
lymph	NULL
node	NULL
,	NULL
liver	NULL
,	NULL
adrenal	NULL
,	NULL
soft	NULL
tissue	NULL
,	NULL
and	NULL
bone	NULL
.	NULL

ANOVA	NULL
(	NULL
20	NULL
)	NULL
was	NULL
used	NULL
to	NULL
test	NULL
for	NULL
a	NULL
significant	NULL
variability	NULL
within	NULL
and	NULL
between	NULL
control	NULL
subjects	NULL
run	NULL
on	NULL
the	NULL
same	NULL
Western	NULL
blot	NULL
(	NULL
three	NULL
subjects	NULL
and	NULL
three	NULL
time	NULL
points	NULL
)	NULL
.	NULL

The	NULL
F	NULL
statistic	NULL
(	NULL
21	NULL
)	NULL
was	NULL
used	NULL
to	NULL
test	NULL
for	NULL
a	NULL
difference	NULL
in	NULL
variances	NULL
between	NULL
different	NULL
samples	NULL
and	NULL
within	NULL
the	NULL
same	NULL
sample	NULL
run	NULL
on	NULL
this	NULL
same	NULL
Western	NULL
blot	NULL
.	NULL

The	NULL
Mantel-Haenszel	NULL
log-rank	NULL
test	NULL
(	NULL
22	NULL
)	NULL
was	NULL
used	NULL
to	NULL
test	NULL
for	NULL
a	NULL
survival	NULL
difference	NULL
by	NULL
response	NULL
.	NULL

RESULTS	NULL
Patient	NULL
Characteristics	NULL
.	NULL

-	NULL
A	NULL
total	NULL
of	NULL
54	NULL
patients	NULL
with	NULL
met-astatic/unresectable	NULL
RCC	NULL
and	NULL
11	NULL
patients	NULL
after	NULL
resection	NULL
of	NULL
all	NULL
disease	NULL
were	NULL
studied	NULL
from	NULL
October	NULL
1993	NULL
to	NULL
August	NULL
1997	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Forty-two	NULL
individuals	NULL
were	NULL
participants	NULL
in	NULL
two	NULL
different	NULL
clinical	NULL
trials	NULL
using	NULL
slightly	NULL
different	NULL
regimens	NULL
of	NULL
rIL-2	NULL
and	NULL
IFNa	NULL
with/without	NULL
5-FU	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Seven	NULL
patients	NULL
were	NULL
treated	NULL
with	NULL
rIL-2	NULL
and	NULL
IFNa	NULL
,	NULL
and	NULL
the	NULL
remaining	NULL
35	NULL
received	NULL
this	NULL
same	NULL
combination	NULL
plus	NULL
5-FU	NULL
.	NULL

In	NULL
this	NULL
group	NULL
,	NULL
all	NULL
patients	NULL
had	NULL
an	NULL
Eastern	NULL
Cooperative	NULL
Oncology	NULL
Group	NULL
performance	NULL
status	NULL
of	NULL
<	NULL
1	NULL
(	NULL
0-17	NULL
patients	NULL
and	NULL
1-25	NULL
patients	NULL
)	NULL
.	NULL

The	NULL
majority	NULL
(	NULL
n	NULL
=	NULL
32	NULL
)	NULL
of	NULL
these	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

Clinical	NULL
Cancer	NULL
Research	NULL
2341	NULL
Pi	NULL
RS	NULL
Pt	NULL
.	NULL

WA	NULL
Pt	NULL
.	NULL

DC	NULL
P	NULL
D8	NULL
Dis	NULL
+	NULL
P	NULL
D8	NULL
D15	NULL
+	NULL
P	NULL
D8	NULL
D15	NULL
+	NULL
wto	NULL
see	NULL
umes	NULL
emee	NULL
G-	NULL
TCRE	NULL
ab	NULL
-o	NULL
and	NULL
B	NULL
<	NULL
Â«	NULL
4-	NULL
CD3	NULL
:	NULL
-o	NULL
a	NULL
Â»	NULL
Â«	NULL
ih	NULL
Â«	NULL
Â»	NULL
<	NULL
Â«	NULL
s4-	NULL
COSc	NULL
tous	NULL
wwe	NULL
#	NULL
-G-	NULL
CD3C	NULL
3000	NULL
3000	NULL
3000	NULL
2000	NULL
2000	NULL
2000	NULL
1000	NULL
1000	NULL
1000	NULL
Â°	NULL
Pre	NULL
Ds	NULL
D15	NULL
+	NULL
Pre	NULL
D8	NULL
D15	NULL
+	NULL
Â°	NULL
Pre	NULL
D8	NULL
D15	NULL
+	NULL
Fig	NULL
.	NULL

3	NULL
Western	NULL
blots	NULL
and	NULL
corresponding	NULL
densitometry	NULL
data	NULL
in	NULL
three	NULL
patients	NULL
receiving	NULL
therapy	NULL
with	NULL
rIL-2	NULL
,	NULL
IFNa	NULL
,	NULL
and	NULL
5-FU	NULL
.	NULL

Levels	NULL
of	NULL
TCR4	NULL
(	NULL
MB	NULL
)	NULL
and	NULL
CD3e	NULL
(	NULL
]	NULL
)	NULL
in	NULL
T	NULL
cells	NULL
obtained	NULL
on	NULL
days	NULL
0	NULL
,	NULL
8	NULL
,	NULL
and	NULL
15	NULL
of	NULL
cycle	NULL
1	NULL
,	NULL
with	NULL
an	NULL
accompanying	NULL
control	NULL
,	NULL
are	NULL
illustrated	NULL
.	NULL

Increasing	NULL
levels	NULL
of	NULL
TCRL	NULL
during	NULL
cytokine	NULL
therapy	NULL
are	NULL
demonstrated	NULL
in	NULL
each	NULL
patient	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
CD3e	NULL
showed	NULL
minimal	NULL
variation	NULL
.	NULL

Pr	NULL
.	NULL

WA	NULL
,	NULL
patient	NULL
W.	NULL
A.	NULL
;	NULL
Pr	NULL
.	NULL

DO	NULL
,	NULL
patient	NULL
D.	NULL
O.	NULL
;	NULL
Pr	NULL
.	NULL

RS	NULL
,	NULL
patient	NULL
R.	NULL
$	NULL
.	NULL

D8	NULL
,	NULL
day	NULL
8	NULL
;	NULL
D15	NULL
,	NULL
day	NULL
15	NULL
.	NULL

0.11	NULL
Sess	NULL
.	NULL

Sms	NULL
g	NULL
0.61	NULL
Ã©	NULL
0.51	NULL
22	NULL
gq	NULL
04	NULL
Z	NULL
?	NULL

5	NULL
os|	NULL
|	NULL
W	NULL
2	NULL
0.2	NULL
}	NULL
g	NULL
0.0	NULL
~	NULL
led	NULL
15	NULL
Day	NULL
of	NULL
Therapy	NULL
Fig	NULL
.	NULL

4	NULL
-	NULL
Alterations	NULL
in	NULL
TCRL	NULL
in	NULL
patients	NULL
treated	NULL
with	NULL
IL-2/IFNa	NULL
*	NULL
5-FU	NULL
(	NULL
means	NULL
;	NULL
bars	NULL
,	NULL
SE	NULL
)	NULL
.	NULL

Changes	NULL
in	NULL
relative	NULL
levels	NULL
of	NULL
TCR	NULL
{	NULL
(	NULL
determined	NULL
by	NULL
densitometry	NULL
)	NULL
on	NULL
days	NULL
8	NULL
and	NULL
15	NULL
of	NULL
cytokine	NULL
therapy	NULL
in	NULL
29	NULL
patients	NULL
.	NULL

Alterations	NULL
in	NULL
TCRL	NULL
levels	NULL
were	NULL
calculated	NULL
as	NULL
follows	NULL
:	NULL
TCRipg	NULL
,	NULL
;	NULL
js	NULL
TCRL	NULL
,	NULL
,	NULL
Control	NULL
.	NULL

Relative	NULL
levels	NULL
of	NULL
TCR	NULL
{	NULL
were	NULL
then	NULL
compared	NULL
with	NULL
pretherapy	NULL
values	NULL
for	NULL
all	NULL
patient	NULL
for	NULL
day	NULL
8	NULL
(	NULL
D8	NULL
;	NULL
P	NULL
=	NULL
0.187	NULL
)	NULL
and	NULL
day	NULL
15	NULL
(	NULL
D15	NULL
;	NULL
P	NULL
=	NULL
0.002	NULL
)	NULL
.	NULL

individuals	NULL
were	NULL
previously	NULL
untreated	NULL
.	NULL

Twelve	NULL
patients	NULL
with	NULL
metastatic	NULL
and	NULL
locally	NULL
advanced	NULL
RCC	NULL
prior	NULL
to	NULL
surgery	NULL
or	NULL
systemic	NULL
therapy	NULL
were	NULL
also	NULL
studied	NULL
.	NULL

Finally	NULL
,	NULL
11	NULL
patients	NULL
with	NULL
locally	NULL
advanced	NULL
or	NULL
metastatic	NULL
disease	NULL
who	NULL
underwent	NULL
resection	NULL
of	NULL
all	NULL
visible	NULL
disease	NULL
were	NULL
studied	NULL
prior	NULL
to	NULL
treatment	NULL
in	NULL
a	NULL
pilot	NULL
study	NULL
of	NULL
adjuvant	NULL
r	NULL
[	NULL
L-2	NULL
.	NULL

Frequency	NULL
and	NULL
Extent	NULL
of	NULL
Signaling	NULL
Element	NULL
Defects	NULL
in	NULL
Peripheral	NULL
Blood-derived	NULL
T	NULL
Cells	NULL
from	NULL
RCC	NULL
Patients	NULL
.	NULL

Previously	NULL
,	NULL
in	NULL
a	NULL
small	NULL
number	NULL
of	NULL
RCC	NULL
patients	NULL
,	NULL
we	NULL
reported	NULL
that	NULL
the	NULL
levels	NULL
of	NULL
TCR4L	NULL
,	NULL
p56	NULL
``	NULL
*	NULL
,	NULL
and	NULL
p59	NULL
``	NULL
were	NULL
decreased	NULL
in	NULL
PBL-Ts	NULL
from	NULL
some	NULL
individuals	NULL
.	NULL

This	NULL
report	NULL
extends	NULL
these	NULL
findings	NULL
and	NULL
determined	NULL
the	NULL
levels	NULL
as	NULL
well	NULL
as	NULL
the	NULL
frequency	NULL
of	NULL
altered	NULL
expression	NULL
of	NULL
TCRL	NULL
,	NULL
CD3e	NULL
,	NULL
and	NULL
p56	NULL
``	NULL
*	NULL
in	NULL
PBL-T	NULL
's	NULL
from	NULL
RCC	NULL
patients	NULL
.	NULL

Twenty-five	NULL
patients	NULL
receiving	NULL
rIL-2/IFNa-based	NULL
therapy	NULL
and	NULL
four	NULL
additional	NULL
patients	NULL
with	NULL
locally	NULL
advanced	NULL
and/or	NULL
metastatic	NULL
disease	NULL
were	NULL
studied	NULL
.	NULL

Data	NULL
on	NULL
these	NULL
29	NULL
patients	NULL
was	NULL
pooled	NULL
and	NULL
examined	NULL
for	NULL
differences	NULL
between	NULL
patients	NULL
and	NULL
normal	NULL
controls	NULL
.	NULL

Correlations	NULL
of	NULL
pretreatment	NULL
protein	NULL
levels	NULL
with	NULL
survival	NULL
,	NULL
clinical	NULL
response	NULL
,	NULL
number	NULL
or	NULL
location	NULL
of	NULL
metastatic	NULL
sites	NULL
,	NULL
performance	NULL
status	NULL
,	NULL
prior	NULL
therapy	NULL
,	NULL
age	NULL
,	NULL
gender	NULL
,	NULL
and	NULL
nephrectomy	NULL
status	NULL
were	NULL
carried	NULL
out	NULL
.	NULL

Fig	NULL
.	NULL

1	NULL
demonstrates	NULL
Western	NULL
blots	NULL
illustrating	NULL
levels	NULL
of	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
in	NULL
PBL-Ts	NULL
from	NULL
selected	NULL
RCC	NULL
patients	NULL
compared	NULL
with	NULL
controls	NULL
.	NULL

In	NULL
the	NULL
29	NULL
patients	NULL
examined	NULL
,	NULL
normal	NULL
levels	NULL
of	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
were	NULL
displayed	NULL
in	NULL
59	NULL
and	NULL
55	NULL
%	NULL
of	NULL
individuals	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
remaining	NULL
individuals	NULL
expressed	NULL
detectable	NULL
but	NULL
reduced	NULL
levels	NULL
of	NULL
these	NULL
two	NULL
signaling	NULL
elements	NULL
.	NULL

In	NULL
2	NULL
of	NULL
29	NULL
patients	NULL
,	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
were	NULL
not	NULL
detected	NULL
in	NULL
PBL-Ts	NULL
.	NULL

CD3e	NULL
levels	NULL
(	NULL
determined	NULL
on	NULL
23	NULL
patients	NULL
)	NULL
remain	NULL
relatively	NULL
constant	NULL
in	NULL
most	NULL
instances	NULL
;	NULL
however	NULL
,	NULL
some	NULL
variability	NULL
in	NULL
these	NULL
levels	NULL
was	NULL
also	NULL
noted	NULL
.	NULL

Visual	NULL
inspection	NULL
of	NULL
the	NULL
Western	NULL
blots	NULL
clearly	NULL
demonstrated	NULL
some	NULL
decrease	NULL
in	NULL
the	NULL
various	NULL
signaling	NULL
molecules	NULL
compared	NULL
with	NULL
controls	NULL
as	NULL
follows	NULL
:	NULL
TCRL	NULL
,	NULL
12	NULL
of	NULL
29	NULL
(	NULL
41	NULL
%	NULL
)	NULL
;	NULL
p56	NULL
``	NULL
,	NULL
13	NULL
of	NULL
29	NULL
(	NULL
45	NULL
%	NULL
)	NULL
;	NULL
and	NULL
CD3e	NULL
,	NULL
2	NULL
of	NULL
23	NULL
(	NULL
8	NULL
%	NULL
)	NULL
.	NULL

Because	NULL
visual	NULL
inspection	NULL
of	NULL
Western	NULL
blots	NULL
is	NULL
at	NULL
best	NULL
qualitative	NULL
,	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

2342	NULL
Signal	NULL
Transduction	NULL
Abnormalities	NULL
in	NULL
T	NULL
Cells	NULL
Age	NULL
Matched	NULL
Normals	NULL
(	NULL
JB	NULL
)	NULL
PA	NULL
Os	NULL
-	NULL
Cs	NULL
Media	NULL
__	NULL
Q5	NULL
20	NULL
40	NULL
C1	NULL
co	NULL
W	NULL
C1	NULL
(	NULL
JF	NULL
)	NULL
P/I	NULL
CD3	NULL
CD3	NULL
Media	NULL
QS	NULL
20	NULL
40	NULL
C1	NULL
C2	NULL
(	NULL
AJ	NULL
)	NULL
P/	NULL
P/	NULL
D3	NULL
COB	NULL
Meda	NULL
_	NULL
as	NULL
20	NULL
20	NULL
40	NULL
C+	NULL
(	NULL
wall	NULL
|	NULL
ls	NULL
C1	NULL
c2	NULL
fï¬	NULL
'	NULL
.	NULL

â	NULL
CZ	NULL
(	NULL
AE	NULL
)	NULL
PA	NULL
CD3	NULL
as	NULL
40	NULL
C1	NULL
-	NULL
doe	NULL
now	NULL
c2	NULL
l	NULL
c2	NULL
aoa	NULL
u	NULL
Media	NULL
as	NULL
20	NULL
20	NULL
inseg	NULL
)	NULL
hout	NULL
RCC	NULL
Patients	NULL
Normal	NULL
PBL	NULL
(	NULL
KG	NULL
)	NULL
Day	NULL
O	NULL
PBL	NULL
P/	NULL
PA	NULL
PA	NULL
PA	NULL
PA	NULL
PA	NULL
o25	NULL
20	NULL
Media	NULL
_Q25___	NULL
_	NULL
OS____20	NULL
Normal	NULL
PBL	NULL
(	NULL
LR	NULL
)	NULL
Day	NULL
0	NULL
PBL	NULL
PA	NULL
P/	NULL
P/	NULL
PA	NULL
PA	NULL
Media	NULL
__	NULL
025	NULL
as	NULL
_209_	NULL
Media	NULL
_	NULL
QS	NULL
20	NULL
Normal	NULL
PBL	NULL
(	NULL
CS	NULL
)	NULL
Day	NULL
0	NULL
PBL	NULL
PA	NULL
_	NULL
Pi	NULL
_	NULL
s	NULL
as	NULL
ss	NULL
_	NULL
O3	NULL
40__	NULL
Meda	NULL
___	NULL
20	NULL
40	NULL
tui	NULL
jr=	NULL
%	NULL
rind	NULL
Normal	NULL
PBL	NULL
(	NULL
KC	NULL
)	NULL
Day	NULL
0	NULL
PBL	NULL
PA	NULL
_	NULL
PL	NULL
_	NULL
os	NULL
P/	NULL
Os	NULL
MÃ©dia	NULL
___	NULL
Q5	NULL
__20	NULL
__	NULL
20	NULL
_	NULL
Media	NULL
__	NULL
20	NULL
20	NULL
2	NULL
et	NULL
!	NULL

Fig	NULL
.	NULL

5	NULL
EMSAs	NULL
are	NULL
illustrated	NULL
that	NULL
were	NULL
performed	NULL
on	NULL
T	NULL
cells	NULL
from	NULL
four	NULL
normal	NULL
individuals	NULL
and	NULL
four	NULL
RCC	NULL
patients	NULL
(	NULL
indicated	NULL
by	NULL
initials	NULL
)	NULL
plus	NULL
four	NULL
age-matched	NULL
controls	NULL
.	NULL

The	NULL
studies	NULL
demonstrate	NULL
induction	NULL
of	NULL
6B-specific	NULL
binding	NULL
complexes	NULL
after	NULL
stimulation	NULL
with	NULL
PMA	NULL
(	NULL
P	NULL
,	NULL
10	NULL
pg/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
I	NULL
,	NULL
0.75	NULL
g/ml	NULL
)	NULL
or	NULL
cross-linked	NULL
anti-CD3	NULL
monoclonal	NULL
antibody	NULL
(	NULL
CD3	NULL
)	NULL
.	NULL

Various	NULL
incubation	NULL
times	NULL
including	NULL
0.25	NULL
,	NULL
0.5	NULL
,	NULL
2.0	NULL
and	NULL
4.0	NULL
h	NULL
are	NULL
illustrated	NULL
.	NULL

T	NULL
cells	NULL
from	NULL
the	NULL
four	NULL
age-matched	NULL
control	NULL
individuals	NULL
demonstrate	NULL
normal	NULL
induction	NULL
of	NULL
C1	NULL
(	NULL
RelA	NULL
and	NULL
NFkBI1	NULL
homodimer	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
T	NULL
cells	NULL
from	NULL
four	NULL
different	NULL
normal	NULL
and	NULL
four	NULL
RCC	NULL
patients	NULL
demonstrate	NULL
normal	NULL
NFxB	NULL
activation	NULL
in	NULL
the	NULL
former	NULL
group	NULL
compared	NULL
with	NULL
no	NULL
induction	NULL
of	NULL
the	NULL
C1	NULL
and	NULL
C2	NULL
nuclear	NULL
complexes	NULL
after	NULL
stimulation	NULL
in	NULL
the	NULL
patients	NULL
.	NULL

densitometry	NULL
scanning	NULL
was	NULL
used	NULL
to	NULL
provide	NULL
relative	NULL
estimates	NULL
of	NULL
signaling	NULL
molecule	NULL
levels	NULL
.	NULL

Fig	NULL
.	NULL

1	NULL
illustrates	NULL
Western	NULL
blots	NULL
and	NULL
relative	NULL
levels	NULL
of	NULL
these	NULL
proteins	NULL
based	NULL
on	NULL
the	NULL
densitometry	NULL
data	NULL
in	NULL
selected	NULL
patients	NULL
(	NULL
prior	NULL
to	NULL
therapy	NULL
)	NULL
and	NULL
normal	NULL
individuals	NULL
.	NULL

For	NULL
the	NULL
entire	NULL
group	NULL
of	NULL
patients	NULL
,	NULL
CD3e	NULL
levels	NULL
were	NULL
not	NULL
significantly	NULL
different	NULL
compared	NULL
with	NULL
control	NULL
individuals	NULL
(	NULL
P	NULL
=	NULL
0.131	NULL
)	NULL
;	NULL
however	NULL
,	NULL
(	NULL
P	NULL
=	NULL
0.029	NULL
)	NULL
and	NULL
p56	NULL
``	NULL
*	NULL
(	NULL
P	NULL
=	NULL
0.029	NULL
)	NULL
were	NULL
lower	NULL
.	NULL

The	NULL
correlations	NULL
of	NULL
pretreatment	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
levels	NULL
with	NULL
various	NULL
clinical	NULL
characteristics	NULL
and	NULL
objective	NULL
responses	NULL
(	NULL
3	NULL
of	NULL
25	NULL
partial	NULL
responses	NULL
)	NULL
in	NULL
patients	NULL
receiving	NULL
cytokine	NULL
therapy	NULL
were	NULL
also	NULL
investigated	NULL
.	NULL

Lower	NULL
levels	NULL
of	NULL
TCR	NULL
were	NULL
associated	NULL
with	NULL
the	NULL
presence	NULL
of	NULL
bone	NULL
metastases	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

No	NULL
significant	NULL
decreases	NULL
were	NULL
associated	NULL
with	NULL
the	NULL
other	NULL
variables	NULL
such	NULL
as	NULL
number	NULL
of	NULL
metastatic	NULL
sites	NULL
or	NULL
nephrectomy	NULL
status	NULL
.	NULL

Additionally	NULL
,	NULL
higher	NULL
levels	NULL
of	NULL
p56	NULL
``	NULL
and	NULL
TCRL	NULL
were	NULL
not	NULL
associated	NULL
with	NULL
clinical	NULL
response	NULL
(	NULL
P	NULL
=	NULL
0.068	NULL
and	NULL
0.223	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Because	NULL
variability	NULL
of	NULL
protein	NULL
levels	NULL
from	NULL
experiment	NULL
to	NULL
experiment	NULL
is	NULL
an	NULL
issue	NULL
,	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
was	NULL
examined	NULL
in	NULL
PBL-T	NULL
cells	NULL
isolated	NULL
from	NULL
healthy	NULL
volunteers	NULL
.	NULL

Some	NULL
variability	NULL
in	NULL
levels	NULL
of	NULL
CD3e	NULL
,	NULL
p56	NULL
``	NULL
,	NULL
and	NULL
TCRL	NULL
were	NULL
observed	NULL
in	NULL
T	NULL
cells	NULL
isolated	NULL
from	NULL
five	NULL
different	NULL
normal	NULL
individuals	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
stability	NULL
of	NULL
signal	NULL
transduction	NULL
molecule	NULL
levels	NULL
over	NULL
time	NULL
in	NULL
three	NULL
control	NULL
individuals	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
without	NULL
cancer	NULL
was	NULL
also	NULL
studied	NULL
longitudinally	NULL
at	NULL
three	NULL
different	NULL
time	NULL
points	NULL
(	NULL
days	NULL
0	NULL
,	NULL
8	NULL
,	NULL
and	NULL
15	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
illustrate	NULL
that	NULL
levels	NULL
of	NULL
TCRL	NULL
,	NULL
p56	NULL
``	NULL
**	NULL
,	NULL
and	NULL
CD3e	NULL
varied	NULL
minimally	NULL
within	NULL
a	NULL
single	NULL
individual	NULL
over	NULL
a	NULL
time	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

Clinical	NULL
Cancer	NULL
Research	NULL
2343	NULL
Fig	NULL
.	NULL

6	NULL
Identification	NULL
-	NULL
of	NULL
|	NULL
the	NULL
NFB	NULL
family	NULL
members	NULL
that	NULL
are	NULL
present	NULL
in	NULL
the	NULL
6B-specific	NULL
complexes	NULL
of	NULL
patient	NULL
and	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

-	NULL
Supershift	NULL
-	NULL
experiments	NULL
were	NULL
performed	NULL
on	NULL
nuclear	NULL
ex	NULL
No	NULL
Antibody	NULL
Anti-NFxBI	NULL
Rabbit	NULL
IgG	NULL
Anti-NFKB1	NULL
+	NULL
Anti-c-Rel	NULL
Anti-	NULL
+	NULL
Anti-RelIA	NULL
Anti-ReIA	NULL
+	NULL
Anti-c-Rel	NULL
Anti-ReIA	NULL
Anti-c-Rel	NULL
tracts	NULL
from	NULL
normal	NULL
and	NULL
patient	NULL
PBL-T	NULL
cells	NULL
after	NULL
4	NULL
h	NULL
of	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
.	NULL

Standard	NULL
EMSA	NULL
procedure	NULL
was	NULL
followed	NULL
with	NULL
the	NULL
exception	NULL
that	NULL
25	NULL
pl	NULL
of	NULL
reaction	NULL
mixture	NULL
were	NULL
preincubated	NULL
with	NULL
2	NULL
pl	NULL
(	NULL
2	NULL
pg	NULL
)	NULL
of	NULL
the	NULL
appropriate	NULL
antibody	NULL
at	NULL
4Â°C	NULL
for	NULL
15	NULL
min	NULL
.	NULL

The	NULL
labeled	NULL
probe	NULL
(	NULL
IL2Ra	NULL
sequence	NULL
)	NULL
was	NULL
then	NULL
added	NULL
before	NULL
electrophoresis	NULL
.	NULL

The	NULL
antibodies	NULL
used	NULL
included	NULL
anti-NFxB1	NULL
,	NULL
anti-RelA	NULL
,	NULL
and	NULL
an-ti-c-Rel	NULL
.	NULL

Normal	NULL
rabbit	NULL
serum	NULL
(	NULL
2	NULL
pg	NULL
;	NULL
Jackson	NULL
Immuno	NULL
Research	NULL
Laboratory	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
.	NULL

Nuclear	NULL
extract	NULL
from	NULL
normal	NULL
activated	NULL
T	NULL
cells	NULL
that	NULL
was	NULL
not	NULL
incubated	NULL
with	NULL
any	NULL
antibody	NULL
was	NULL
included	NULL
in	NULL
every	NULL
experiment	NULL
to	NULL
show	NULL
the	NULL
migration	NULL
of	NULL
C1	NULL
and	NULL
C2	NULL
complexes	NULL
.	NULL

Identical	NULL
results	NULL
to	NULL
those	NULL
shown	NULL
in	NULL
this	NULL
figure	NULL
were	NULL
obtained	NULL
in	NULL
a	NULL
second	NULL
experiment	NULL
.	NULL

A	NULL
:	NULL
Normal	NULL
PBL	NULL
B	NULL
:	NULL
RCC	NULL
PBL	NULL
period	NULL
of	NULL
2	NULL
weeks	NULL
.	NULL

When	NULL
the	NULL
densitometry	NULL
data	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
were	NULL
analyzed	NULL
,	NULL
there	NULL
was	NULL
significant	NULL
variability	NULL
between	NULL
individual	NULL
control	NULL
subjects	NULL
(	NULL
TCRL	NULL
,	NULL
P	NULL
=	NULL
0.018	NULL
;	NULL
p56	NULL
``	NULL
,	NULL
P	NULL
=	NULL
0.46	NULL
;	NULL
and	NULL
CD3e	NULL
,	NULL
P	NULL
=	NULL
0.031	NULL
)	NULL
,	NULL
this	NULL
was	NULL
not	NULL
seen	NULL
within	NULL
the	NULL
same	NULL
subjects	NULL
tested	NULL
on	NULL
separate	NULL
days	NULL
(	NULL
TCR4L	NULL
,	NULL
P	NULL
=	NULL
0.38	NULL
;	NULL
p56	NULL
``	NULL
,	NULL
P	NULL
=	NULL
0.26	NULL
;	NULL
CD3e	NULL
,	NULL
P	NULL
=	NULL
0.94	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
signaling	NULL
molecule	NULL
levels	NULL
remain	NULL
relatively	NULL
constant	NULL
within	NULL
a	NULL
normal	NULL
individual	NULL
over	NULL
time	NULL
.	NULL

Treatment	NULL
with	NULL
rIL-2/IFNa-based	NULL
Regimens	NULL
Produces	NULL
an	NULL
Increase	NULL
in	NULL
the	NULL
Expression	NULL
of	NULL
TCR	NULL
in	NULL
Patient-derived	NULL
T	NULL
Cells	NULL
.	NULL

-	NULL
The	NULL
effects	NULL
of	NULL
cytokine	NULL
administration	NULL
on	NULL
PBL-T	NULL
levels	NULL
of	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
were	NULL
then	NULL
investigated	NULL
in	NULL
21	NULL
patients	NULL
in	NULL
whom	NULL
serial	NULL
studies	NULL
were	NULL
available	NULL
.	NULL

Fig	NULL
.	NULL

3	NULL
illustrates	NULL
selected	NULL
patients	NULL
who	NULL
were	NULL
receiving	NULL
rIL-2/IFNa	NULL
regimens	NULL
.	NULL

Increases	NULL
of	NULL
TCR	NULL
are	NULL
evident	NULL
on	NULL
inspection	NULL
of	NULL
the	NULL
Western	NULL
blots	NULL
and	NULL
are	NULL
also	NULL
demonstrated	NULL
by	NULL
the	NULL
corresponding	NULL
densitometry	NULL
readings	NULL
.	NULL

In	NULL
the	NULL
12	NULL
patients	NULL
with	NULL
reduced	NULL
levels	NULL
of	NULL
TCRL	NULL
before	NULL
therapy	NULL
,	NULL
increases	NULL
were	NULL
noted	NULL
in	NULL
nine	NULL
after	NULL
initiation	NULL
of	NULL
treatment	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
levels	NULL
of	NULL
CD3e	NULL
remained	NULL
relatively	NULL
constant	NULL
.	NULL

Changes	NULL
in	NULL
protein	NULL
levels	NULL
during	NULL
cytokine	NULL
administration	NULL
(	NULL
rIL-2/IFNa	NULL
Â«	NULL
regimens	NULL
)	NULL
were	NULL
then	NULL
examined	NULL
by	NULL
comparing	NULL
relative	NULL
levels	NULL
on	NULL
days	NULL
8	NULL
and	NULL
15	NULL
to	NULL
baseline	NULL
.	NULL

Fig	NULL
.	NULL

4	NULL
illustrates	NULL
changes	NULL
in	NULL
the	NULL
Â®	NULL
#	NULL
#	NULL
Â¥4.ia	NULL
C1	NULL
Â»	NULL
|	NULL
#	NULL
relative	NULL
levels	NULL
of	NULL
TCR	NULL
{	NULL
levels	NULL
determined	NULL
by	NULL
densitometry	NULL
and	NULL
demonstrates	NULL
that	NULL
by	NULL
day	NULL
15	NULL
of	NULL
treatment	NULL
,	NULL
these	NULL
increased	NULL
significantly	NULL
compared	NULL
with	NULL
baseline	NULL
(	NULL
P	NULL
=	NULL
0.002	NULL
)	NULL
.	NULL

No	NULL
significant	NULL
changes	NULL
in	NULL
p56	NULL
``	NULL
levels	NULL
during	NULL
treatment	NULL
were	NULL
found	NULL
.	NULL

Impaired	NULL
activation	NULL
of	NULL
NFB	NULL
in	NULL
PBL-T	NULL
Cells	NULL
from	NULL
RCC	NULL
Patients	NULL
.	NULL

-	NULL
In	NULL
view	NULL
of	NULL
our	NULL
previous	NULL
report	NULL
(	NULL
10	NULL
)	NULL
noting	NULL
abnormal	NULL
activation	NULL
of	NULL
NFKkB/Re	NULL
!	NULL

l	NULL
proteins	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
28	NULL
patients	NULL
with	NULL
RCC	NULL
were	NULL
then	NULL
investigated	NULL
to	NULL
determine	NULL
the	NULL
induction	NULL
of	NULL
6B	NULL
binding	NULL
activity	NULL
.	NULL

Twenty	NULL
patients	NULL
prior	NULL
to	NULL
therapy	NULL
with	NULL
rIL-2/	NULL
IFNa/5-FU	NULL
and	NULL
8	NULL
additional	NULL
untreated	NULL
patients	NULL
with	NULL
metastatic	NULL
RCC	NULL
were	NULL
studied	NULL
.	NULL

In	NULL
the	NULL
20	NULL
patients	NULL
receiving	NULL
cytokine	NULL
therapy	NULL
,	NULL
three	NULL
were	NULL
simultaneously	NULL
investigated	NULL
for	NULL
alterations	NULL
in	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
.	NULL

PBL-Ts	NULL
were	NULL
isolated	NULL
and	NULL
stimulated	NULL
with	NULL
PMA/	NULL
ionomycin	NULL
prior	NULL
to	NULL
performing	NULL
EMSA	NULL
(	NULL
25	NULL
patients	NULL
)	NULL
.	NULL

Normal	NULL
PBL-T	NULL
cells	NULL
show	NULL
two	NULL
6B-specific	NULL
binding	NULL
complexes	NULL
after	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Antibody-mediated	NULL
supershift	NULL
experiments	NULL
showed	NULL
that	NULL
the	NULL
slower	NULL
moving	NULL
complex	NULL
(	NULL
C1	NULL
)	NULL
was	NULL
composed	NULL
of	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
and	NULL
NFkBI1	NULL
(	NULL
p50	NULL
)	NULL
.	NULL

Anti-NFkBIl	NULL
and	NULL
anti-RelA	NULL
shifted	NULL
the	NULL
C1	NULL
complex	NULL
effectively	NULL
,	NULL
whereas	NULL
anti-cRel	NULL
had	NULL
very	NULL
little	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

The	NULL
faster	NULL
migrating	NULL
complex	NULL
(	NULL
C2	NULL
)	NULL
was	NULL
a	NULL
homodimer	NULL
of	NULL
NFkBI	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
because	NULL
antibody	NULL
to	NULL
NFkBI1	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

2344	NULL
Signal	NULL
Transduction	NULL
Abnormalities	NULL
in	NULL
T	NULL
Cells	NULL
RCC-PBL	NULL
Normal-PBL	NULL
(	NULL
DM	NULL
)	NULL
(	NULL
VA	NULL
)	NULL
(	NULL
DD	NULL
)	NULL
(	NULL
JS	NULL
)	NULL
(	NULL
AP	NULL
)	NULL
4	NULL
-	NULL
2	NULL
3	NULL
NFxB	NULL
Activation	NULL
=	NULL
-	NULL
-	NULL
_-	NULL
_-	NULL
-	NULL
+o	NULL
+	NULL
+	NULL
Westem	NULL
Blotting	NULL
_	NULL
~~	NULL
``	NULL
*	NULL
``	NULL
Â®	NULL
Â«	NULL
--	NULL
-	NULL
_	NULL
Â«	NULL
--	NULL
=	NULL
am	NULL
Â»	NULL
Â«	NULL
-	NULL
Â»	NULL
psglck	NULL
Â«	NULL
s-	NULL
au	NULL
Â»	NULL
Â«	NULL
s	NULL
Â»	NULL
Â«	NULL
--	NULL
GPD	NULL
aso	NULL
cus	NULL
an	NULL
TCRK	NULL
CD3e	NULL
Fig	NULL
.	NULL

7	NULL
Five	NULL
selected	NULL
patients	NULL
in	NULL
whom	NULL
studies	NULL
of	NULL
TCRL	NULL
,	NULL
pS6**	NULL
,	NULL
and	NULL
CD3e	NULL
levels	NULL
and	NULL
NFxB	NULL
activation	NULL
performed	NULL
concomitantly	NULL
.	NULL

PBL-T	NULL
cells	NULL
were	NULL
isolated	NULL
,	NULL
and	NULL
Western	NULL
blots	NULL
to	NULL
detect	NULL
levels	NULL
of	NULL
TCR4L	NULL
,	NULL
pS6	NULL
``	NULL
*	NULL
,	NULL
and	NULL
CD3e	NULL
were	NULL
performed	NULL
.	NULL

Additionally	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
4	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
jg/m	NULL
!	NULL
)	NULL

,	NULL
ionomycin	NULL
(	NULL
0.75	NULL
pg/ml	NULL
)	NULL
,	NULL
or	NULL
cross-linked	NULL
monoclonal	NULL
anti-CD3	NULL
antibody	NULL
prior	NULL
to	NULL
isolating	NULL
cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
.	NULL

The	NULL
nuclear	NULL
extracts	NULL
were	NULL
used	NULL
for	NULL
EMSA	NULL
to	NULL
detect	NULL
nuclear	NULL
expression	NULL
of	NULL
6B-specific	NULL
binding	NULL
activity	NULL
.	NULL

This	NULL
is	NULL
indicated	NULL
as	NULL
positive	NULL
(	NULL
+	NULL
)	NULL
or	NULL
negative	NULL
(	NULL
-	NULL
)	NULL
and	NULL
illustrates	NULL
abnormal	NULL
NFB	NULL
activation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
normal	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
``	NULL
*	NULL
levels	NULL
.	NULL

Parentheses	NULL
,	NULL
patients	NULL
'	NULL
initials	NULL
.	NULL

almost	NULL
completely	NULL
shifted	NULL
this	NULL
complex	NULL
,	NULL
whereas	NULL
antibodies	NULL
to	NULL
RelA	NULL
and	NULL
c-Rel	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

In	NULL
some	NULL
patients	NULL
,	NULL
there	NULL
was	NULL
expression	NULL
of	NULL
C2	NULL
but	NULL
not	NULL
C1	NULL
after	NULL
stimulation	NULL
.	NULL

Characterization	NULL
of	NULL
this	NULL
complex	NULL
revealed	NULL
that	NULL
it	NULL
was	NULL
composed	NULL
of	NULL
NFkBI	NULL
because	NULL
it	NULL
was	NULL
supershifted	NULL
with	NULL
anti-NFBI1	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Abnormal	NULL
activation	NULL
of	NULL
NFxB	NULL
after	NULL
stimulation	NULL
with	NULL
PMA/ionomycin	NULL
was	NULL
present	NULL
in	NULL
15	NULL
of	NULL
25	NULL
(	NULL
60	NULL
%	NULL
)	NULL
individuals	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
representative	NULL
data	NULL
)	NULL
.	NULL

In	NULL
PBL-Ts	NULL
from	NULL
15	NULL
patients	NULL
with	NULL
abnormal	NULL
NFKB	NULL
activation	NULL
,	NULL
12	NULL
did	NULL
not	NULL
demonstrate	NULL
detectable	NULL
6B-specific	NULL
binding	NULL
activity	NULL
after	NULL
stimulation	NULL
with	NULL
PMA/ionomycin	NULL
.	NULL

In	NULL
three	NULL
additional	NULL
patients	NULL
with	NULL
abnormal	NULL
NFkB	NULL
activation	NULL
,	NULL
there	NULL
was	NULL
induction	NULL
of	NULL
RelA/NFkBI1	NULL
(	NULL
C1	NULL
complex	NULL
)	NULL
,	NULL
but	NULL
the	NULL
duration	NULL
was	NULL
short	NULL
lived	NULL
.	NULL

Activation	NULL
of	NULL
NFkB	NULL
after	NULL
stimulation	NULL
with	NULL
cross-linked	NULL
anti-CD3	NULL
antibody	NULL
was	NULL
performed	NULL
in	NULL
nine	NULL
of	NULL
the	NULL
patients	NULL
studied	NULL
,	NULL
and	NULL
impaired	NULL
activation	NULL
was	NULL
observed	NULL
in	NULL
PBL-Ts	NULL
from	NULL
six	NULL
.	NULL

Activation	NULL
of	NULL
NFKB	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
a	NULL
group	NULL
of	NULL
age-matched	NULL
healthy	NULL
donors	NULL
(	NULL
n	NULL
=	NULL
8	NULL
;	NULL
mean	NULL
age	NULL
,	NULL
55.5	NULL
years	NULL
;	NULL
range	NULL
,	NULL
50	NULL
to	NULL
62	NULL
)	NULL
was	NULL
also	NULL
performed	NULL
to	NULL
control	NULL
for	NULL
the	NULL
possible	NULL
reduced	NULL
activation	NULL
due	NULL
to	NULL
the	NULL
age	NULL
of	NULL
the	NULL
RCC	NULL
patients	NULL
(	NULL
mean	NULL
,	NULL
53.6	NULL
years	NULL
;	NULL
range	NULL
,	NULL
39	NULL
to	NULL
62	NULL
)	NULL
.	NULL

Seven	NULL
of	NULL
eight	NULL
controls	NULL
displayed	NULL
normal	NULL
activation	NULL
of	NULL
NFB	NULL
to	NULL
PMA/ionomycin	NULL
or	NULL
cross-linked	NULL
anti-CD3	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Simultaneous	NULL
studies	NULL
of	NULL
NFB	NULL
activation	NULL
and	NULL
PBL-T	NULL
levels	NULL
of	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
were	NULL
performed	NULL
in	NULL
14	NULL
patients	NULL
.	NULL

These	NULL
individuals	NULL
included	NULL
three	NULL
patients	NULL
with	NULL
metastatic	NULL
disease	NULL
and	NULL
11	NULL
who	NULL
had	NULL
recently	NULL
undergone	NULL
surgery	NULL
for	NULL
removal	NULL
of	NULL
their	NULL
primary	NULL
tumor	NULL
or	NULL
metastatic	NULL
disease	NULL
.	NULL

In	NULL
nine	NULL
individuals	NULL
,	NULL
and	NULL
p56	NULL
``	NULL
levels	NULL
were	NULL
normal	NULL
,	NULL
as	NULL
was	NULL
NFB	NULL
activation	NULL
.	NULL

In	NULL
five	NULL
patients	NULL
,	NULL
TCR	NULL
and	NULL
p56	NULL
``	NULL
levels	NULL
also	NULL
appeared	NULL
normal	NULL
,	NULL
but	NULL
NFxB	NULL
activation	NULL
was	NULL
impaired	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
abnormal	NULL
activation	NULL
of	NULL
NFB	NULL
was	NULL
found	NULL
despite	NULL
normal	NULL
levels	NULL
of	NULL
TCR4	NULL
.	NULL

Treatment	NULL
with	NULL
rIL-2/IFNa-based	NULL
Therapy	NULL
Allows	NULL
Normal	NULL
Activation	NULL
of	NULL
NFB	NULL
in	NULL
Patient	NULL
T	NULL
Cells	NULL
.	NULL

Studies	NULL
of	NULL
NFxB	NULL
activation	NULL
were	NULL
performed	NULL
in	NULL
nine	NULL
patients	NULL
at	NULL
baseline	NULL
and	NULL
on	NULL
day	NULL
15	NULL
of	NULL
rIL-2/IFNa/5-FU	NULL
therapy	NULL
.	NULL

In	NULL
six	NULL
individuals	NULL
with	NULL
abnormal	NULL
studies	NULL
at	NULL
baseline	NULL
,	NULL
activation	NULL
of	NULL
NFB	NULL
was	NULL
noted	NULL
in	NULL
four	NULL
after	NULL
therapy	NULL
(	NULL
patients	NULL
M.	NULL
M.	NULL
,	NULL
V.	NULL
A.	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
and	NULL
E.	NULL
W.	NULL
;	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

In	NULL
one	NULL
of	NULL
the	NULL
patients	NULL
in	NULL
whom	NULL
NFkB	NULL
activation	NULL
became	NULL
normal	NULL
,	NULL
a	NULL
partial	NULL
clinical	NULL
response	NULL
was	NULL
seen	NULL
.	NULL

In	NULL
the	NULL
three	NULL
additional	NULL
patients	NULL
,	NULL
activation	NULL
of	NULL
NFB	NULL
was	NULL
normal	NULL
at	NULL
baseline	NULL
and	NULL
did	NULL
not	NULL
change	NULL
during	NULL
therapy	NULL
.	NULL

These	NULL
data	NULL
are	NULL
preliminary	NULL
but	NULL
suggest	NULL
that	NULL
during	NULL
cytokine	NULL
therapy	NULL
,	NULL
the	NULL
impaired	NULL
induction	NULL
of	NULL
6B	NULL
binding	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
some	NULL
selected	NULL
patients	NULL
with	NULL
metastatic	NULL
RCC	NULL
is	NULL
reversible	NULL
.	NULL

DISCUSSION	NULL
The	NULL
presence	NULL
of	NULL
immune	NULL
dysfunction	NULL
in	NULL
animals	NULL
and	NULL
patients	NULL
with	NULL
advanced	NULL
malignancies	NULL
has	NULL
been	NULL
recognized	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
,	NULL
but	NULL
the	NULL
responsible	NULL
mechanisms	NULL
are	NULL
unclear	NULL
.	NULL

A	NULL
variety	NULL
of	NULL
cell-mediated	NULL
functions	NULL
such	NULL
as	NULL
cytotoxicity	NULL
(	NULL
12	NULL
)	NULL
and	NULL
cytokine	NULL
production	NULL
(	NULL
14	NULL
)	NULL
are	NULL
deficient	NULL
,	NULL
and	NULL
the	NULL
possibility	NULL
these	NULL
abnormalities	NULL
may	NULL
have	NULL
a	NULL
negative	NULL
impact	NULL
on	NULL
therapy	NULL
and/or	NULL
patient	NULL
outcome	NULL
does	NULL
exist	NULL
.	NULL

Abnormalities	NULL
of	NULL
signal	NULL
transduction	NULL
in	NULL
T-lymphocytes	NULL
from	NULL
spleens	NULL
of	NULL
mice	NULL
with	NULL
progressive	NULL
tumors	NULL
(	NULL
1	NULL
,	NULL
25	NULL
)	NULL
have	NULL
been	NULL
demonstrated	NULL
,	NULL
including	NULL
decreased	NULL
levels	NULL
of	NULL
the	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
p56	NULL
``	NULL
and	NULL
p59	NULL
``	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
&	NULL
chain	NULL
of	NULL
the	NULL
TCR	NULL
CD3	NULL
complex	NULL
.	NULL

In	NULL
humans	NULL
,	NULL
similar	NULL
abnormalities	NULL
in	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
and	NULL
PBLs	NULL
from	NULL
individuals	NULL
with	NULL
RCC	NULL
(	NULL
2	NULL
,	NULL
5	NULL
)	NULL
,	NULL
colon	NULL
cancer	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
,	NULL
ovarian	NULL
cancer	NULL
(	NULL
6	NULL
)	NULL
,	NULL
melanoma	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
,	NULL
and	NULL
Hodgkin	NULL
's	NULL
disease	NULL
(	NULL
26	NULL
)	NULL
have	NULL
been	NULL
described	NULL
.	NULL

Reduced	NULL
TCRE/	NULL
CD3-associated	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
p56	NULL
``	NULL
kinase	NULL
activity	NULL
,	NULL
and	NULL
cytokine	NULL
production	NULL
have	NULL
also	NULL
been	NULL
reported	NULL
in	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
from	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
patients	NULL
,	NULL
although	NULL
they	NULL
express	NULL
normal	NULL
levels	NULL
of	NULL
TCR	NULL
{	NULL
-associated	NULL
kinases	NULL
and	NULL
TCRL	NULL
(	NULL
27	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
signaling	NULL
defects	NULL
may	NULL
provide	NULL
an	NULL
explanation	NULL
for	NULL
the	NULL
functional	NULL
abnormalities	NULL
reported	NULL
previously	NULL
,	NULL
but	NULL
correlations	NULL
between	NULL
these	NULL
findings	NULL
remain	NULL
preliminary	NULL
.	NULL

Several	NULL
reports	NULL
have	NULL
noted	NULL
an	NULL
association	NULL
of	NULL
these	NULL
defects	NULL
with	NULL
decreased	NULL
cytokine	NULL
production	NULL
(	NULL
4	NULL
,	NULL
5	NULL
,	NULL
26	NULL
)	NULL
or	NULL
cell	NULL
proliferation	NULL
(	NULL
27	NULL
)	NULL
.	NULL

It	NULL
is	NULL
also	NULL
possible	NULL
that	NULL
the	NULL
reduced	NULL
expression	NULL
of	NULL
in	NULL
tumor-associated	NULL
T	NULL
cells	NULL
may	NULL
occur	NULL
secondary	NULL
to	NULL
the	NULL
release	NULL
of	NULL
proteases	NULL
from	NULL
granulocytes	NULL
and	NULL
monocytes	NULL
during	NULL
protein	NULL
extraction	NULL
(	NULL
28	NULL
)	NULL
.	NULL

The	NULL
results	NULL
in	NULL
the	NULL
present	NULL
report	NULL
suggest	NULL
that	NULL
levels	NULL
of	NULL
TCRG	NULL
and	NULL
p56	NULL
``	NULL
are	NULL
reduced	NULL
in	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
in	NULL
selected	NULL
patients	NULL
with	NULL
advanced	NULL
renal	NULL
cell	NULL
carcinoma	NULL
,	NULL
although	NULL
virtually	NULL
all	NULL
patients	NULL
express	NULL
these	NULL
signaling	NULL
elements	NULL
.	NULL

When	NULL
the	NULL
entire	NULL
population	NULL
was	NULL
compared	NULL
with	NULL
normal	NULL
individuals	NULL
,	NULL
the	NULL
relative	NULL
levels	NULL
of	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
but	NULL
not	NULL
CD3e	NULL
were	NULL
significantly	NULL
lower	NULL
.	NULL

A	NULL
reduction	NULL
of	NULL
TCR	NULL
&	NULL
in	NULL
T	NULL
cells	NULL
was	NULL
noted	NULL
in	NULL
~41	NULL
%	NULL
of	NULL
patients	NULL
,	NULL
similar	NULL
to	NULL
results	NULL
reported	NULL
previously	NULL
for	NULL
RCC	NULL
patients	NULL
using	NULL
flow	NULL
cytometry	NULL
(	NULL
29	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
attempted	NULL
to	NULL
semiquantitate	NULL
levels	NULL
of	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
and	NULL
correlate	NULL
them	NULL
with	NULL
clinical	NULL
findings	NULL
and	NULL
response	NULL
.	NULL

Significant	NULL
associations	NULL
were	NULL
not	NULL
found	NULL
,	NULL
except	NULL
for	NULL
decreased	NULL
levels	NULL
of	NULL
TCR4	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
bone	NULL
metastases	NULL
.	NULL

No	NULL
association	NULL
with	NULL
response	NULL
was	NULL
found	NULL
,	NULL
but	NULL
the	NULL
numbers	NULL
of	NULL
patients	NULL
responding	NULL
represent	NULL
=15	NULL
%	NULL
of	NULL
the	NULL
population	NULL
.	NULL

The	NULL
patient	NULL
population	NULL
in	NULL
our	NULL
study	NULL
was	NULL
composed	NULL
of	NULL
individuals	NULL
with	NULL
unresectable	NULL
and	NULL
advanced	NULL
RCC	NULL
;	NULL
therefore	NULL
,	NULL
differences	NULL
between	NULL
early	NULL
and	NULL
advanced	NULL
disease	NULL
stages	NULL
as	NULL
reported	NULL
by	NULL
Mat-suda	NULL
er	NULL
al	NULL
.	NULL

(	NULL
9	NULL
)	NULL
for	NULL
colorectal	NULL
cancer	NULL
patients	NULL
were	NULL
not	NULL
detectable	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
use	NULL
of	NULL
Western	NULL
blots	NULL
to	NULL
assess	NULL
signaling	NULL
molecule	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

Clinical	NULL
Cancer	NULL
Research	NULL
2345	NULL
Fig	NULL
.	NULL

8	NULL
EMSAs	NULL
are	NULL
illustrated	NULL
that	NULL
were	NULL
performed	NULL
on	NULL
T	NULL
cells	NULL
from	NULL
six	NULL
control	NULL
individuals	NULL
and	NULL
six	NULL
RCC	NULL
patients	NULL
(	NULL
indicated	NULL
by	NULL
initials	NULL
)	NULL
.	NULL

Patient	NULL
T	NULL
cells	NULL
were	NULL
obtained	NULL
prior	NULL
to	NULL
cytokine	NULL
therapy	NULL
(	NULL
day	NULL
0	NULL
)	NULL
and	NULL
on	NULL
day	NULL
15	NULL
of	NULL
cycle	NULL
1	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
either	NULL
PMA	NULL
(	NULL
P	NULL
,	NULL
10	NULL
pg/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
/	NULL
,	NULL
0.75	NULL
pg/ml	NULL
)	NULL
or	NULL
cross-linked	NULL
anti-CD3	NULL
monoclonal	NULL
antibody	NULL
(	NULL
CD3	NULL
)	NULL
.	NULL

Various	NULL
incubation	NULL
times	NULL
including	NULL
0.25	NULL
,	NULL
0.5	NULL
,	NULL
2.0	NULL
,	NULL
and	NULL
4.0	NULL
h	NULL
are	NULL
illustrated	NULL
.	NULL

The	NULL
six	NULL
RCC	NULL
patients	NULL
demonstrate	NULL
abnormal	NULL
induction	NULL
of	NULL
the	NULL
C1	NULL
complex	NULL
prior	NULL
to	NULL
therapy	NULL
.	NULL

During	NULL
therapy	NULL
,	NULL
activation	NULL
of	NULL
NFB	NULL
was	NULL
noted	NULL
in	NULL
four	NULL
patients	NULL
(	NULL
MM	NULL
,	NULL
VA	NULL
,	NULL
RH	NULL
,	NULL
and	NULL
EW	NULL
)	NULL
on	NULL
day	NULL
15	NULL
of	NULL
treatment	NULL
.	NULL

Normal	NULL
PBL	NULL
(	NULL
MM	NULL
)	NULL
Day	NULL
0	NULL
PBL	NULL
(	NULL
MM	NULL
)	NULL
Day	NULL
15	NULL
PBL	NULL
P/	NULL
PA	NULL
D3	NULL
PA	NULL
Â©3	NULL
D3	NULL
P/I	NULL
A	NULL
O3	NULL
Media	NULL
as	NULL
20	NULL
20	NULL
-	NULL
Media	NULL
_	NULL
20	NULL
20	NULL
40	NULL
_	NULL
Meda	NULL
as	NULL
20	NULL
20	NULL
C1	NULL
C2	NULL
Normal	NULL
PBI	NULL
(	NULL
VA	NULL
)	NULL
Day	NULL
0	NULL
PBL	NULL
(	NULL
VA	NULL
)	NULL
Day	NULL
15	NULL
PBL	NULL
c	NULL
P/	NULL
PAL	NULL
_	NULL
P/L	NULL
_	NULL
P/	NULL
P/	NULL
P	NULL
Meda	NULL
_	NULL
Q5	NULL
_	NULL
20	NULL
-	NULL
Meda	NULL
O25	NULL
-	NULL
OS	NULL
-	NULL
20	NULL
-	NULL
40	NULL
Meda	NULL
O25	NULL
OSs	NULL
-	NULL
20	NULL
C1	NULL
C2	NULL
Normal	NULL
PBL	NULL
(	NULL
RH	NULL
)	NULL
Day	NULL
0	NULL
PBL	NULL
(	NULL
RH	NULL
)	NULL
Day	NULL
15	NULL
PBL	NULL
P/	NULL
PAM	NULL
_	NULL
O3	NULL
C	NULL
Aes	NULL
P/L	NULL
O	NULL
PA	NULL
__	NULL
os	NULL
Media	NULL
_	NULL
Q5	NULL
__	NULL
20	NULL
_	NULL
20	NULL
Meda	NULL
QS	NULL
_	NULL
20	NULL
-	NULL
20	NULL
-	NULL
Meda	NULL
-	NULL
as	NULL
20	NULL
-	NULL
20	NULL
C1	NULL
C2	NULL
Normal	NULL
PBL	NULL
(	NULL
EW	NULL
)	NULL
Day	NULL
O	NULL
PBL	NULL
(	NULL
EW	NULL
)	NULL
Day	NULL
15	NULL
PBL	NULL
PA	NULL
(	NULL
es	NULL
PA	NULL
ers	NULL
]	NULL
A	NULL
os	NULL
Meda	NULL
_	NULL
as	NULL
20	NULL
-	NULL
20	NULL
Media	NULL
-	NULL
QS	NULL
20	NULL
-	NULL
20	NULL
Meda	NULL
-	NULL
Q5	NULL
_	NULL
20	NULL
20	NULL
C1	NULL
C2	NULL
Normal	NULL
PBL	NULL
(	NULL
RW	NULL
)	NULL
Day	NULL
0	NULL
PBL	NULL
(	NULL
RW	NULL
)	NULL
Day	NULL
15	NULL
PBL	NULL
Pi	NULL
_	NULL
os	NULL
Gs	NULL
mM	NULL
Os	NULL
Os	NULL
M	NULL
-	NULL
o	NULL
O3	NULL
Media	NULL
_	NULL
QS	NULL
20	NULL
40	NULL
-__	NULL
Media	NULL
20	NULL
20	NULL
-	NULL
40	NULL
_	NULL
Meda	NULL
-	NULL
QS	NULL
20	NULL
40	NULL
C1	NULL
C2	NULL
Normal	NULL
PBL	NULL
(	NULL
RG	NULL
)	NULL
Day	NULL
0	NULL
PBL	NULL
(	NULL
RG	NULL
)	NULL
Day	NULL
15	NULL
PBL	NULL
PA	NULL
_	NULL
PA	NULL
A	NULL
M	NULL
Meda	NULL
-	NULL
Q5	NULL
_	NULL
20	NULL
-	NULL
Meda	NULL
QS	NULL
_	NULL
20	NULL
-	NULL
Meda	NULL
O5	NULL
_	NULL
20	NULL
C1	NULL
C2	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

2346	NULL
Signal	NULL
Transduction	NULL
Abnormalities	NULL
in	NULL
T	NULL
Cells	NULL
levels	NULL
may	NULL
be	NULL
less	NULL
sensitive	NULL
that	NULL
other	NULL
techniques	NULL
and	NULL
therefore	NULL
contribute	NULL
to	NULL
the	NULL
findings	NULL
in	NULL
the	NULL
present	NULL
report	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
therapy	NULL
with	NULL
rIL-2/IFNa-containing	NULL
regimens	NULL
on	NULL
levels	NULL
of	NULL
TCR	NULL
{	NULL
-associated	NULL
signaling	NULL
molecules	NULL
were	NULL
also	NULL
examined	NULL
.	NULL

Increases	NULL
in	NULL
T	NULL
cell	NULL
levels	NULL
of	NULL
TCRE	NULL
on	NULL
day	NULL
15	NULL
of	NULL
cycle	NULL
one	NULL
(	NULL
versus	NULL
baseline	NULL
)	NULL
were	NULL
seen	NULL
.	NULL

Rabinowich	NULL
et	NULL
al	NULL
.	NULL

(	NULL
3	NULL
)	NULL
found	NULL
no	NULL
effect	NULL
of	NULL
rIL-2	NULL
therapy	NULL
on	NULL
TCRL	NULL
levels	NULL
in	NULL
melanoma	NULL
patients	NULL
;	NULL
however	NULL
,	NULL
in	NULL
responding	NULL
patients	NULL
with	NULL
low	NULL
levels	NULL
before	NULL
therapy	NULL
,	NULL
normalization	NULL
was	NULL
reported	NULL
.	NULL

Farace	NULL
et	NULL
al	NULL
.	NULL

(	NULL
29	NULL
)	NULL
reported	NULL
that	NULL
IL-2	NULL
therapy	NULL
did	NULL
not	NULL
produce	NULL
a	NULL
significant	NULL
change	NULL
in	NULL
TCRL	NULL
expression	NULL
.	NULL

The	NULL
findings	NULL
in	NULL
our	NULL
study	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
different	NULL
cytokine	NULL
regimen	NULL
used	NULL
,	NULL
the	NULL
timing	NULL
of	NULL
our	NULL
studies	NULL
(	NULL
day	NULL
15	NULL
)	NULL
,	NULL
or	NULL
the	NULL
methodology	NULL
used	NULL
.	NULL

In	NULL
view	NULL
of	NULL
previous	NULL
reports	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
,	NULL
the	NULL
NFB	NULL
family	NULL
members	NULL
were	NULL
also	NULL
examined	NULL
.	NULL

NFkB	NULL
is	NULL
a	NULL
transcription	NULL
factor	NULL
that	NULL
regulates	NULL
multiple	NULL
genes	NULL
important	NULL
for	NULL
T-cell	NULL
function	NULL
and	NULL
growth	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
NFB	NULL
complexes	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
where	NULL
they	NULL
regulate	NULL
transcription	NULL
of	NULL
kB-dependent	NULL
genes	NULL
.	NULL

Examination	NULL
of	NULL
NFkB	NULL
activation	NULL
demonstrated	NULL
abnormalities	NULL
in	NULL
>	NULL
50	NULL
%	NULL
of	NULL
patients	NULL
.	NULL

The	NULL
most	NULL
prominent	NULL
alteration	NULL
was	NULL
in	NULL
the	NULL
nuclear	NULL
localization	NULL
of	NULL
NFkBI1/ReIA	NULL
dimers	NULL
(	NULL
C1	NULL
complex	NULL
)	NULL
as	NULL
defined	NULL
by	NULL
EMSA	NULL
.	NULL

Western	NULL
blot	NULL
experiments	NULL
demonstrated	NULL
that	NULL
after	NULL
stimulation	NULL
,	NULL
RelA	NULL
failed	NULL
to	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
although	NULL
it	NULL
was	NULL
present	NULL
in	NULL
the	NULL
cytoplasm	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
effects	NULL
of	NULL
impaired	NULL
NFkB	NULL
activation	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
C2	NULL
complex	NULL
(	NULL
p50	NULL
homodimers	NULL
)	NULL
may	NULL
produce	NULL
suppression	NULL
of	NULL
gene	NULL
expression	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Age-matched	NULL
normal	NULL
donors	NULL
were	NULL
included	NULL
in	NULL
this	NULL
study	NULL
because	NULL
previous	NULL
reports	NULL
have	NULL
shown	NULL
that	NULL
in	NULL
older	NULL
individuals	NULL
(	NULL
272	NULL
years	NULL
)	NULL
,	NULL
there	NULL
are	NULL
alterations	NULL
in	NULL
immune	NULL
function	NULL
and	NULL
reduced	NULL
activation	NULL
of	NULL
AP-1	NULL
(	NULL
32	NULL
)	NULL
and	NULL
NFB	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
in	NULL
healthy	NULL
donors	NULL
(	NULL
mean	NULL
age	NULL
,	NULL
52	NULL
years	NULL
)	NULL
there	NULL
is	NULL
nuclear	NULL
localization	NULL
of	NULL
the	NULL
C1	NULL
complex	NULL
RelA	NULL
)	NULL
after	NULL
stimulation	NULL
with	NULL
either	NULL
PMA/ionomycin	NULL
or	NULL
anti-CD3	NULL
antibody	NULL
in	NULL
seven	NULL
of	NULL
eight	NULL
individuals	NULL
studied	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
minor	NULL
alterations	NULL
in	NULL
NFxB	NULL
activation	NULL
in	NULL
healthy	NULL
individuals	NULL
in	NULL
their	NULL
fifth	NULL
and	NULL
sixth	NULL
decades	NULL
is	NULL
infrequent	NULL
and	NULL
does	NULL
not	NULL
account	NULL
for	NULL
the	NULL
defect	NULL
observed	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
.	NULL

The	NULL
alterations	NULL
in	NULL
NFB	NULL
activation	NULL
appear	NULL
to	NULL
be	NULL
downstream	NULL
of	NULL
alterations	NULL
in	NULL
TCR	NULL
{	NULL
-associated	NULL
signaling	NULL
events	NULL
.	NULL

It	NULL
is	NULL
unlikely	NULL
that	NULL
the	NULL
reduced	NULL
expression	NULL
of	NULL
and	NULL
p56	NULL
``	NULL
contribute	NULL
to	NULL
the	NULL
impaired	NULL
activation	NULL
of	NULL
NFB	NULL
by	NULL
decreasing	NULL
phosphorylation	NULL
of	NULL
I6B	NULL
proteins	NULL
and	NULL
thereby	NULL
preventing	NULL
dissociation	NULL
of	NULL
NFKB	NULL
from	NULL
its	NULL
inhibitor	NULL
(	NULL
34	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
14	NULL
patients	NULL
were	NULL
simultaneously	NULL
investigated	NULL
for	NULL
NFB	NULL
activation	NULL
and	NULL
expression	NULL
.	NULL

In	NULL
nine	NULL
cases	NULL
,	NULL
all	NULL
studies	NULL
were	NULL
normal	NULL
,	NULL
and	NULL
in	NULL
the	NULL
other	NULL
five	NULL
patients	NULL
,	NULL
NFB	NULL
activation	NULL
via	NULL
the	NULL
TCREL	NULL
or	NULL
by	NULL
PMA/Ionomycin	NULL
was	NULL
impaired	NULL
despite	NULL
normal	NULL
levels	NULL
of	NULL
TCRL	NULL
and	NULL
p56	NULL
``	NULL
**	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
impaired	NULL
NFxB	NULL
activation	NULL
was	NULL
observed	NULL
with	NULL
PMA/ionomycin	NULL
further	NULL
suggests	NULL
that	NULL
the	NULL
defect	NULL
in	NULL
NFKB	NULL
is	NULL
downstream	NULL
of	NULL
signaling	NULL
linked	NULL
to	NULL
TCRL	NULL
because	NULL
these	NULL
events	NULL
are	NULL
bypassed	NULL
by	NULL
PMA/ionomycin	NULL
activation	NULL
.	NULL

A	NULL
recent	NULL
report	NULL
by	NULL
Correa	NULL
et	NULL
al	NULL
.	NULL

(	NULL
35	NULL
)	NULL
noted	NULL
a	NULL
similar	NULL
dissociation	NULL
of	NULL
NFB	NULL
activation	NULL
and	NULL
TCRL	NULL
reduction	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
tumor-bearing	NULL
mice	NULL
.	NULL

Attempts	NULL
to	NULL
correlate	NULL
these	NULL
findings	NULL
with	NULL
T-cell	NULL
cytokine	NULL
production	NULL
patterns	NULL
are	NULL
under	NULL
way	NULL
.	NULL

This	NULL
study	NULL
and	NULL
others	NULL
(	NULL
2-8	NULL
)	NULL
clearly	NULL
demonstrate	NULL
abnormal	NULL
levels	NULL
of	NULL
various	NULL
signaling	NULL
molecules	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
advanced	NULL
malignancies	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
different	NULL
patterns	NULL
will	NULL
be	NULL
found	NULL
in	NULL
various	NULL
neoplasms	NULL
,	NULL
and	NULL
until	NULL
the	NULL
mechanisms	NULL
responsible	NULL
for	NULL
these	NULL
changes	NULL
are	NULL
clarified	NULL
,	NULL
the	NULL
significance	NULL
of	NULL
these	NULL
findings	NULL
remains	NULL
unclear	NULL
.	NULL

Tumor-derived	NULL
soluble	NULL
factors	NULL
that	NULL
impair	NULL
T-lymphocyte	NULL
functions	NULL
have	NULL
been	NULL
demonstrated	NULL
(	NULL
36	NULL
,	NULL
37	NULL
)	NULL
,	NULL
and	NULL
recent	NULL
reports	NULL
show	NULL
that	NULL
hydrogen	NULL
peroxide	NULL
produced	NULL
by	NULL
tumor-associated	NULL
macrophages	NULL
can	NULL
inhibit	NULL
the	NULL
expression	NULL
of	NULL
TCRE	NULL
(	NULL
38	NULL
,	NULL
39	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
cell-cell	NULL
contact	NULL
between	NULL
T	NULL
cells	NULL
and	NULL
a	NULL
human	NULL
tumor	NULL
cell	NULL
was	NULL
shown	NULL
to	NULL
suppress	NULL
the	NULL
expression	NULL
of	NULL
TCRL	NULL
and	NULL
cytolytic	NULL
activity	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Studies	NULL
from	NULL
our	NULL
laboratory	NULL
suggest	NULL
that	NULL
the	NULL
impairment	NULL
in	NULL
NFKB	NULL
activation	NULL
noted	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
can	NULL
be	NULL
reproduced	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
by	NULL
supernatants	NULL
from	NULL
cultured	NULL
renal	NULL
tumor	NULL
explants	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Additional	NULL
studies	NULL
are	NULL
required	NULL
to	NULL
further	NULL
determine	NULL
the	NULL
extent	NULL
of	NULL
these	NULL
defects	NULL
,	NULL
determine	NULL
their	NULL
relevance	NULL
to	NULL
stage	NULL
and	NULL
outcome	NULL
with	NULL
therapy	NULL
,	NULL
and	NULL
the	NULL
responsible	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
involved	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Mizoguchi	NULL
,	NULL
H.	NULL
,	NULL
O'Shea	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Loeffler	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
McVicar	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
and	NULL
Ochoa	NULL
,	NULL
A.	NULL
C.	NULL
Alterations	NULL
in	NULL
signal	NULL
transduction	NULL
molecules	NULL
in	NULL
T	NULL
lymphocytes	NULL
from	NULL
tumor	NULL
bearing	NULL
mice	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
258	NULL
:	NULL
1795-1798	NULL
,	NULL
1992	NULL
.	NULL

2	NULL
.	NULL

Finke	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Zea	NULL
,	NULL
A.	NULL
H.	NULL
,	NULL
Stanley	NULL
,	NULL
J.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Mizoguchi	NULL
,	NULL
H.	NULL
,	NULL
Tubbs	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
Wiitrout	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
O'Shea	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Kudoh	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Klein	NULL
,	NULL
E.	NULL
Loss	NULL
of	NULL
T-cell	NULL
receptor	NULL
Â£	NULL
chain	NULL
and	NULL
p56'*	NULL
in	NULL
T-cells	NULL
infiltrating	NULL
human	NULL
renal	NULL
cell	NULL
carcinoma	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
53	NULL
:	NULL
5613-5616	NULL
,	NULL
1993	NULL
.	NULL

3	NULL
.	NULL

Rabinowich	NULL
,	NULL
H.	NULL
,	NULL
Banks	NULL
,	NULL
M.	NULL
,	NULL
Reichert	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
Logan	NULL
,	NULL
T.	NULL
F.	NULL
,	NULL
Kirkwood	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Whiteside	NULL
,	NULL
T.	NULL
L.	NULL
Expression	NULL
and	NULL
activity	NULL
of	NULL
signaling	NULL
molecules	NULL
in	NULL
T	NULL
lymphocytes	NULL
obtained	NULL
from	NULL
patients	NULL
with	NULL
metastatic	NULL
melanoma	NULL
before	NULL
and	NULL
after	NULL
interleukin	NULL
2	NULL
therapy	NULL
.	NULL

Clin	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
2	NULL
:	NULL
1263-1274	NULL
,	NULL
1996	NULL
.	NULL

4	NULL
.	NULL

Zea	NULL
,	NULL
A.	NULL
H.	NULL
,	NULL
Curti	NULL
,	NULL
B.	NULL
D.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Alvord	NULL
,	NULL
W.	NULL
G.	NULL
,	NULL
Strobl	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Mizoguchi	NULL
,	NULL
H.	NULL
,	NULL
Creekmore	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
O	NULL
'	NULL
Shea	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Powers	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
Urba	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
and	NULL
Ochoa	NULL
,	NULL
A.	NULL
C.	NULL
Alterations	NULL
in	NULL
T	NULL
cell	NULL
receptor	NULL
and	NULL
signal	NULL
transduction	NULL
molecules	NULL
in	NULL
melanoma	NULL
patients	NULL
.	NULL

Clin	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
/	NULL
:	NULL
1327-1335	NULL
,	NULL
1995	NULL
.	NULL

5	NULL
.	NULL

Tartour	NULL
,	NULL
E.	NULL
,	NULL
Latour	NULL
,	NULL
S.	NULL
,	NULL
Mathiot	NULL
,	NULL
C.	NULL
,	NULL
Thiounn	NULL
,	NULL
N.	NULL
,	NULL
Mosseri	NULL
,	NULL
V.	NULL
,	NULL
Joyeux	NULL
,	NULL
I.	NULL
,	NULL
D'Enghien	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Lee	NULL
,	NULL
R.	NULL
,	NULL
Debre	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Fridman	NULL
,	NULL
W.	NULL
H.	NULL
Variable	NULL
expression	NULL
of	NULL
CD3-	NULL
{	NULL
chain	NULL
in	NULL
tumor	NULL
infiltrating	NULL
lymphocytes	NULL
(	NULL
TIL	NULL
)	NULL
derived	NULL
from	NULL
renal-cell	NULL
carcinoma	NULL
:	NULL
relationship	NULL
with	NULL
TIL	NULL
phenotype	NULL
and	NULL
function	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
63	NULL
:	NULL
205-212	NULL
,	NULL
1995	NULL
.	NULL

6	NULL
.	NULL

Lai	NULL
,	NULL
P.	NULL
,	NULL
Rabinowich	NULL
,	NULL
H.	NULL
,	NULL
Crowley-Nowick	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Bell	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Mantovani	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Whiteside	NULL
,	NULL
T.	NULL
L.	NULL
Alterations	NULL
in	NULL
expression	NULL
and	NULL
function	NULL
of	NULL
signal-transducing	NULL
proteins	NULL
in	NULL
tumor-associated	NULL
T	NULL
and	NULL
natural	NULL
killer	NULL
cells	NULL
in	NULL
patients	NULL
with	NULL
ovarian	NULL
carcinoma	NULL
.	NULL

Clin	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
2	NULL
:	NULL
161-173	NULL
,	NULL
1996	NULL
.	NULL

7	NULL
.	NULL

Renner	NULL
,	NULL
C.	NULL
,	NULL
Ohnesorge	NULL
,	NULL
S.	NULL
,	NULL
Held	NULL
,	NULL
G.	NULL
,	NULL
Bauer	NULL
,	NULL
S.	NULL
,	NULL
Jung	NULL
,	NULL
W.	NULL
,	NULL
Pfitzen-meier	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Pfreundschuh	NULL
,	NULL
M.	NULL
T-cells	NULL
from	NULL
patients	NULL
with	NULL
Hodgkin	NULL
's	NULL
disease	NULL
have	NULL
a	NULL
defective	NULL
T-cell	NULL
receptor	NULL
{	NULL
chain	NULL
expression	NULL
that	NULL
is	NULL
reversible	NULL
by	NULL
T-cell	NULL
stimulation	NULL
with	NULL
CD3	NULL
and	NULL
CD28	NULL
.	NULL

Blood	NULL
,	NULL
88	NULL
:	NULL
236-241	NULL
,	NULL
1996	NULL
.	NULL

8	NULL
.	NULL

Nakagomi	NULL
,	NULL
H.	NULL
,	NULL
Petersson	NULL
,	NULL
M.	NULL
,	NULL
Magnusson	NULL
,	NULL
L.	NULL
,	NULL
Juhlin	NULL
,	NULL
C.	NULL
,	NULL
Matsuda	NULL
,	NULL
M.	NULL
,	NULL
Mellstedt	NULL
,	NULL
H.	NULL
,	NULL
Taupin	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Vivier	NULL
,	NULL
E.	NULL
,	NULL
Anderson	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Kiessling	NULL
,	NULL
R.	NULL
Decreased	NULL
expression	NULL
of	NULL
the	NULL
signal-transducing	NULL
{	NULL
chains	NULL
in	NULL
tumor-infiltrating	NULL
T-cells	NULL
and	NULL
NK	NULL
cells	NULL
of	NULL
patients	NULL
with	NULL
colorectal	NULL
carcinoma	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
53	NULL
:	NULL
5610-5612	NULL
,	NULL
1993	NULL
.	NULL

9	NULL
.	NULL

Matsuda	NULL
,	NULL
M.	NULL
,	NULL
Peterson	NULL
,	NULL
M.	NULL
,	NULL
Lenkei	NULL
,	NULL
R.	NULL
,	NULL
Taupin	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Magnusson	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Mellstedt	NULL
,	NULL
H.	NULL
Alterations	NULL
in	NULL
the	NULL
signal-transducing	NULL
molecules	NULL
of	NULL
T-cells	NULL
and	NULL
NK	NULL
cells	NULL
in	NULL
colorectal	NULL
tumor-infiltrating	NULL
,	NULL
gut	NULL
mucosal	NULL
and	NULL
peripheral	NULL
lymphocytes	NULL
:	NULL
correlation	NULL
with	NULL
the	NULL
stage	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
61	NULL
:	NULL
765-772	NULL
,	NULL
1995	NULL
.	NULL

10	NULL
.	NULL

Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Sica	NULL
,	NULL
A.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
Ye	NULL
,	NULL
J.	NULL
,	NULL
Franco	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Wiltrout	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
and	NULL
Komschlies	NULL
,	NULL
K.	NULL
L.	NULL
Alterations	NULL
in	NULL
NFxB/rel	NULL
family	NULL
proteins	NULL
in	NULL
splenic	NULL
T-cells	NULL
from	NULL
tumor	NULL
bearing	NULL
mice	NULL
and	NULL
reversal	NULL
following	NULL
therapy	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
54	NULL
:	NULL
2969-2972	NULL
,	NULL
1994	NULL
.	NULL

11	NULL
.	NULL

Li	NULL
,	NULL
X.	NULL
,	NULL
Liu	NULL
,	NULL
J.	NULL
,	NULL
Park	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
Hamilton	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Rayman	NULL
,	NULL
P.	NULL
,	NULL
Klein	NULL
,	NULL
E.	NULL
,	NULL
Edinger	NULL
,	NULL
M.	NULL
,	NULL
Tubbs	NULL
,	NULL
R.	NULL
,	NULL
Bukowski	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Finke	NULL
,	NULL
J.	NULL
T-cells	NULL
from	NULL
renal	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

Clinical	NULL
Cancer	NULL
Research	NULL
2347	NULL
cell	NULL
carcinoma	NULL
patients	NULL
exhibit	NULL
an	NULL
abnormal	NULL
pattern	NULL
of	NULL
Â«	NULL
B-specific	NULL
DNA	NULL
binding	NULL
activity	NULL
:	NULL
a	NULL
preliminary	NULL
report	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
54	NULL
:	NULL
5424-5429	NULL
,	NULL
1994	NULL
.	NULL

12	NULL
.	NULL

Miescher	NULL
,	NULL
S.	NULL
,	NULL
Stoeck	NULL
,	NULL
M.	NULL
,	NULL
Qiao	NULL
,	NULL
L.	NULL
,	NULL
Barros	NULL
,	NULL
C.	NULL
,	NULL
Barrelet	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
von	NULL
Fliedner	NULL
,	NULL
V.	NULL
Proliferative	NULL
and	NULL
cytolytic	NULL
potentials	NULL
of	NULL
purified	NULL
human	NULL
tumor-infiltrating	NULL
T-lymphocytes	NULL
.	NULL

Impaired	NULL
response	NULL
to	NULL
mitogen-driven	NULL
stimulation	NULL
despite	NULL
T-cell	NULL
receptor	NULL
expression	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
42	NULL
:	NULL
659-666	NULL
,	NULL
1988	NULL
.	NULL

13	NULL
.	NULL

Alexander	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Kudoh	NULL
,	NULL
S.	NULL
,	NULL
Melsop	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Hamilton	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Edinger	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Tubbs	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
and	NULL
Sica	NULL
,	NULL
D.	NULL
T-cells	NULL
infiltrating	NULL
renal	NULL
cell	NULL
carcinoma	NULL
display	NULL
a	NULL
poor	NULL
proliferative	NULL
response	NULL
even	NULL
though	NULL
they	NULL
can	NULL
produce	NULL
interleukin-2	NULL
and	NULL
express	NULL
interleukin-2	NULL
receptors	NULL
.	NULL

Cancer	NULL
Res..	NULL
53	NULL
:	NULL
1380-1387	NULL
,	NULL
1993	NULL
.	NULL

14	NULL
.	NULL

Vitolo	NULL
,	NULL
D.	NULL
,	NULL
Zerbe	NULL
,	NULL
T.	NULL
,	NULL
Kanbour	NULL
,	NULL
A.	NULL
,	NULL
Dahl	NULL
,	NULL
C.	NULL
,	NULL
Herberman	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
and	NULL
Whiteside	NULL
,	NULL
T.	NULL
L.	NULL
Expression	NULL
of	NULL
mRNA	NULL
for	NULL
cytokines	NULL
in	NULL
tumor-infiltrating	NULL
mononuclear	NULL
cells	NULL
in	NULL
ovarian	NULL
adenocarcinoma	NULL
and	NULL
invasive	NULL
breast	NULL
cancer	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
5/7	NULL
:	NULL
573-580	NULL
,	NULL
1992	NULL
.	NULL

15	NULL
.	NULL

Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Komschlies	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
Cippitelli	NULL
,	NULL
M.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Subleski	NULL
,	NULL
J.	NULL
,	NULL
Ye	NULL
,	NULL
J.	NULL
,	NULL
Sica	NULL
,	NULL
A.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
Wiltrout	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
and	NULL
Ochoa	NULL
,	NULL
A.	NULL
C.	NULL
Gradual	NULL
loss	NULL
of	NULL
T-helper	NULL
1	NULL
populations	NULL
in	NULL
spleen	NULL
of	NULL
mice	NULL
during	NULL
progressive	NULL
tumor	NULL
growth	NULL
.	NULL

J.	NULL
Natl	NULL
.	NULL

Cancer	NULL
Inst	NULL
.	NULL

,	NULL
87	NULL
:	NULL
1478-1483	NULL
,	NULL
1995	NULL
.	NULL

16	NULL
.	NULL

Schreiber	NULL
,	NULL
E.	NULL
,	NULL
Matthias	NULL
,	NULL
E.	NULL
,	NULL
Muller	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
and	NULL
Schaffner	NULL
,	NULL
W.	NULL
Rapid	NULL
detection	NULL
of	NULL
octamer	NULL
binding	NULL
proteins	NULL
with	NULL
Amini-extracts	NULL
prepared	NULL
from	NULL
a	NULL
small	NULL
number	NULL
of	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
,	NULL
77	NULL
:	NULL
6419	NULL
,	NULL
1989	NULL
.	NULL

17	NULL
.	NULL

Osborn	NULL
,	NULL
L.	NULL
,	NULL
Kunkel	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Nabel	NULL
,	NULL
G.	NULL
J.	NULL
Tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
and	NULL
interleukin-1	NULL
stimulate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
kB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
86	NULL
:	NULL
2336-2340	NULL
,	NULL
1989	NULL
.	NULL

18	NULL
.	NULL

Wilcoxon	NULL
,	NULL
F.	NULL
Individual	NULL
comparisons	NULL
by	NULL
ranking	NULL
methods	NULL
.	NULL

Biomet-rics	NULL
,	NULL
7	NULL
;	NULL
80-83	NULL
,	NULL
1945	NULL
.	NULL

19	NULL
.	NULL

Kleinbaum	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
Kupper	NULL
,	NULL
L.	NULL
L.	NULL
,	NULL
and	NULL
Muller	NULL
,	NULL
K.	NULL
E.	NULL
Applied	NULL
Regression	NULL
Analysis	NULL
and	NULL
Other	NULL
Multivariable	NULL
Methods	NULL
,	NULL
pp	NULL
.	NULL

102-143	NULL
.	NULL

Boston	NULL
:	NULL
PWS-KENT	NULL
Publishing	NULL
Company	NULL
,	NULL
1988	NULL
.	NULL

20	NULL
.	NULL

John	NULL
,	NULL
P.	NULL
W.	NULL
Statistical	NULL
Design	NULL
and	NULL
Analysis	NULL
of	NULL
Experiments	NULL
,	NULL
pp	NULL
.	NULL

39-81	NULL
.	NULL

New	NULL
York	NULL
:	NULL
The	NULL
Macmillan	NULL
Company	NULL
,	NULL
1971	NULL
.	NULL

21	NULL
.	NULL

Steel	NULL
,	NULL
R.	NULL
G.	NULL
D.	NULL
,	NULL
and	NULL
Torrie	NULL
,	NULL
J.	NULL
H.	NULL
Principles	NULL
and	NULL
Procedures	NULL
of	NULL
Statistics	NULL
,	NULL
Ed	NULL
.	NULL

2	NULL
,	NULL
pp	NULL
.	NULL

111-113	NULL
.	NULL

New	NULL
York	NULL
:	NULL
McGraw-Hill	NULL
Book	NULL
Co.	NULL
,	NULL
1980	NULL
.	NULL

22	NULL
.	NULL

Mantel	NULL
,	NULL
N.	NULL
Evaluation	NULL
of	NULL
survival	NULL
data	NULL
and	NULL
two	NULL
new	NULL
rank	NULL
order	NULL
statistics	NULL
arising	NULL
in	NULL
its	NULL
consideration	NULL
.	NULL

Cancer	NULL
Chem	NULL
.	NULL

Rep.	NULL
,	NULL
50	NULL
:	NULL
163-170	NULL
,	NULL
1966	NULL
.	NULL

23	NULL
.	NULL

Bukowski	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Olencki	NULL
,	NULL
T.	NULL
,	NULL
Wang	NULL
,	NULL
Q.	NULL
,	NULL
Peereboom	NULL
,	NULL
D.	NULL
,	NULL
Budd	NULL
,	NULL
G.	NULL
T.	NULL
,	NULL
Elson	NULL
,	NULL
P.	NULL
,	NULL
Sandstrom	NULL
,	NULL
K.	NULL
,	NULL
Tuason	NULL
,	NULL
L.	NULL
,	NULL
Rayman	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Tubbs	NULL
,	NULL
R.	NULL
Phase	NULL
II	NULL
trial	NULL
of	NULL
interleukin-2	NULL
and	NULL
interferon-	NULL
in	NULL
patients	NULL
with	NULL
renal	NULL
cell	NULL
carcinoma	NULL
:	NULL
clinical	NULL
results	NULL
and	NULL
immunologic	NULL
correlates	NULL
of	NULL
response	NULL
.	NULL

J	NULL
.	NULL

Immunother	NULL
.	NULL

,	NULL
20	NULL
:	NULL
301-311	NULL
,	NULL
1997	NULL
.	NULL

24	NULL
.	NULL

Olencki	NULL
,	NULL
T.	NULL
,	NULL
Bukowski	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Budd	NULL
,	NULL
G.	NULL
T.	NULL
,	NULL
Peereboom	NULL
,	NULL
D.	NULL
,	NULL
McLain	NULL
,	NULL
D.	NULL
,	NULL
Sandstrom	NULL
,	NULL
K.	NULL
,	NULL
Finke	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Elson	NULL
,	NULL
P.	NULL
Phase	NULL
I/II	NULL
trial	NULL
of	NULL
simultaneously	NULL
administered	NULL
rIL-2/rHulFNa2a	NULL
and	NULL
5-FU	NULL
in	NULL
patients	NULL
(	NULL
PTS	NULL
)	NULL
with	NULL
metastatic	NULL
renal	NULL
cell	NULL
carcinoma	NULL
(	NULL
RCC	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Am	NULL
.	NULL

Soc	NULL
.	NULL

Clin	NULL
.	NULL

Oncol	NULL
.	NULL

,	NULL
15	NULL
:	NULL
263	NULL
,	NULL
1996	NULL
.	NULL

25	NULL
.	NULL

Salvadori	NULL
,	NULL
S.	NULL
,	NULL
Gansbacher	NULL
,	NULL
B.	NULL
,	NULL
Pizzimenti	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
Zier	NULL
,	NULL
K.	NULL
S.	NULL
Abnormal	NULL
signal	NULL
transduction	NULL
by	NULL
T	NULL
cells	NULL
of	NULL
mice	NULL
with	NULL
parental	NULL
tumors	NULL
is	NULL
not	NULL
seen	NULL
in	NULL
mice	NULL
bearing	NULL
IL-2	NULL
secreting	NULL
tumors	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
753	NULL
;	NULL
5176-5182	NULL
,	NULL
1994	NULL
.	NULL

26	NULL
.	NULL

Renner	NULL
,	NULL
C.	NULL
,	NULL
Ohnesorge	NULL
,	NULL
S.	NULL
,	NULL
Held	NULL
,	NULL
G.	NULL
,	NULL
Bauer	NULL
,	NULL
S.	NULL
,	NULL
Jung	NULL
,	NULL
W.	NULL
,	NULL
Pfitzen-meier	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
and	NULL
Pfreundschuh	NULL
,	NULL
M.	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
Hodgkin	NULL
's	NULL
disease	NULL
have	NULL
a	NULL
defective	NULL
T-cell	NULL
receptor	NULL
&	NULL
chain	NULL
expression	NULL
that	NULL
is	NULL
reversible	NULL
by	NULL
T-cell	NULL
stimulation	NULL
with	NULL
CD3	NULL
and	NULL
CD28	NULL
.	NULL

Blood	NULL
,	NULL
88	NULL
:	NULL
236-241	NULL
,	NULL
1996	NULL
.	NULL

27	NULL
.	NULL

Wang	NULL
,	NULL
Q.	NULL
,	NULL
Stanley	NULL
,	NULL
J.	NULL
,	NULL
Kudoh	NULL
,	NULL
S.	NULL
,	NULL
Myles	NULL
,	NULL
J..	NULL
Kolenko	NULL
,	NULL
V.	NULL
,	NULL
Yi	NULL
,	NULL
T.	NULL
,	NULL
Tubbs	NULL
,	NULL
R.	NULL
,	NULL
Bukowski	NULL
,	NULL
R..	NULL
and	NULL
Finke	NULL
,	NULL
J.	NULL
T	NULL
cells	NULL
infiltrating	NULL
non-Hodgkin	NULL
's	NULL
B-cell	NULL
lymphomas	NULL
show	NULL
altered	NULL
tyrosine	NULL
phosphorylation	NULL
pattern	NULL
even	NULL
though	NULL
TCRLCD3*	NULL
associated	NULL
kinases	NULL
are	NULL
present	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
755	NULL
;	NULL
1382-1392	NULL
,	NULL
1995	NULL
.	NULL

28	NULL
.	NULL

Cardi	NULL
,	NULL
G.	NULL
,	NULL
Heaney	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Schnol	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Phillip	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Branda	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
and	NULL
Ernstoff	NULL
,	NULL
M.	NULL
S.	NULL
T-cell	NULL
receptor	NULL
S-chain	NULL
expression	NULL
or	NULL
tumor	NULL
infiltrating	NULL
lymphocytes	NULL
from	NULL
renal	NULL
cell	NULL
carcinoma	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
57	NULL
:	NULL
3517-3519	NULL
,	NULL
1997	NULL
.	NULL

29	NULL
.	NULL

Farace	NULL
,	NULL
F.	NULL
,	NULL
Angevin	NULL
,	NULL
E.	NULL
,	NULL
Vanderplancke	NULL
,	NULL
J.	NULL
,	NULL
Escudier	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Triebel	NULL
,	NULL
F.	NULL
The	NULL
decreased	NULL
expression	NULL
of	NULL
CD3Â¢	NULL
chains	NULL
in	NULL
cancer	NULL
patients	NULL
is	NULL
not	NULL
reversed	NULL
by	NULL
IL-2	NULL
administration	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
59	NULL
:	NULL
752-755	NULL
,	NULL
1994	NULL
.	NULL

30	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
NFB	NULL
:	NULL
ten	NULL
years	NULL
after	NULL
.	NULL

Cell	NULL
,	NULL
87	NULL
:	NULL
13-20	NULL
,	NULL
1996	NULL
.	NULL

31	NULL
.	NULL

Kang	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Tran	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Grilli	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
NFxB	NULL
subunit	NULL
regulation	NULL
in	NULL
nontransformed	NULL
CD4*	NULL
T	NULL
lymphocytes	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
256	NULL
:	NULL
1452-1456	NULL
,	NULL
1992	NULL
.	NULL

32	NULL
.	NULL

Sikora	NULL
,	NULL
E.	NULL
,	NULL
Kaminska	NULL
,	NULL
B.	NULL
,	NULL
Radziszewska	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Kaczmarek	NULL
,	NULL
L.	NULL
Loss	NULL
of	NULL
transcription	NULL
factor	NULL
AP-1	NULL
DNA	NULL
binding	NULL
activity	NULL
during	NULL
lympho-cyte	NULL
aging	NULL
in	NULL
vitro	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

,	NULL
372	NULL
:	NULL
179-182	NULL
,	NULL
1992	NULL
.	NULL

33	NULL
.	NULL

Whisler	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Beiging	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Chen	NULL
,	NULL
M.	NULL
Age-related	NULL
decreases	NULL
in	NULL
IL-2	NULL
production	NULL
by	NULL
human	NULL
T	NULL
cells	NULL
are	NULL
associated	NULL
with	NULL
impaired	NULL
activation	NULL
of	NULL
nuclear	NULL
transcriptional	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
.	NULL

Cell	NULL
Immunol	NULL
.	NULL

,	NULL
169	NULL
:	NULL
185-195	NULL
,	NULL
1996	NULL
.	NULL

34	NULL
.	NULL

Verma	NULL
,	NULL
I.	NULL
M.	NULL
,	NULL
Stevenson	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
Schwarz	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Van	NULL
Antwerp	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Miyamoto	NULL
,	NULL
S.	NULL
Rel/NFxB/I6B	NULL
family	NULL
:	NULL
intimate	NULL
tales	NULL
of	NULL
association	NULL
and	NULL
disassociation	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
9	NULL
:	NULL
2723-2735	NULL
,	NULL
1995	NULL
.	NULL

35	NULL
.	NULL

Correa	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Ochoa	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Mizoguchi	NULL
,	NULL
H.	NULL
,	NULL
Harvey	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
Sequential	NULL
development	NULL
of	NULL
structural	NULL
and	NULL
functional	NULL
alterations	NULL
on	NULL
T-cells	NULL
from	NULL
tumor-bearing	NULL
mice	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
158	NULL
:	NULL
5292-5296	NULL
,	NULL
1997	NULL
.	NULL

36	NULL
.	NULL

Miescher	NULL
,	NULL
S.	NULL
,	NULL
Whiteside	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
Carrel	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Von	NULL
Fliedner	NULL
,	NULL
V.	NULL
Functional	NULL
properties	NULL
of	NULL
tumor-infiltrating	NULL
and	NULL
blood	NULL
lymphocytes	NULL
in	NULL
patients	NULL
with	NULL
solid	NULL
tumors	NULL
:	NULL
effects	NULL
of	NULL
tumor	NULL
cells	NULL
and	NULL
their	NULL
supernatants	NULL
on	NULL
proliferative	NULL
responses	NULL
of	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol..	NULL
736	NULL
:	NULL
1899-1907	NULL
,	NULL
1986	NULL
.	NULL

37	NULL
.	NULL

O'Mahony	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
O'Sullivan	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
O'Connell	NULL
,	NULL
J.	NULL
,	NULL
Cotter	NULL
,	NULL
T.	NULL
G.	NULL
,	NULL
and	NULL
Collins	NULL
,	NULL
J.	NULL
K.	NULL
An	NULL
immune	NULL
suppressive	NULL
factor	NULL
derived	NULL
from	NULL
esopha-geal	NULL
squamous	NULL
carcinoma	NULL
induces	NULL
apoptosis	NULL
in	NULL
normal	NULL
and	NULL
transformed	NULL
cells	NULL
of	NULL
lymphoid	NULL
lineage	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
157	NULL
:	NULL
4847-4856	NULL
,	NULL
1993	NULL
.	NULL

38	NULL
.	NULL

Kono	NULL
,	NULL
K.	NULL
,	NULL
Salazar-Onfray	NULL
,	NULL
F.	NULL
,	NULL
Petersson	NULL
,	NULL
M.	NULL
,	NULL
Hansson	NULL
,	NULL
J.	NULL
,	NULL
Masucci	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Wasserman	NULL
,	NULL
K.	NULL
Hydrogen	NULL
peroxide	NULL
secreted	NULL
by	NULL
tumor-derived	NULL
macrophages	NULL
down-modulates	NULL
signal-transducing	NULL
{	NULL
molecules	NULL
and	NULL
inhibits	NULL
tumor-specific	NULL
T-cell	NULL
and	NULL
natural	NULL
killer	NULL
cell-mediated	NULL
cytotoxicity	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
26	NULL
:	NULL
1308-1313	NULL
,	NULL
1996	NULL
.	NULL

39	NULL
.	NULL

Otsuji	NULL
,	NULL
M.	NULL
,	NULL
Kimura	NULL
,	NULL
Y.	NULL
,	NULL
Aoe	NULL
,	NULL
T.	NULL
,	NULL
Okamoto	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Saito	NULL
,	NULL
T.	NULL
Oxi-dative	NULL
stress	NULL
by	NULL
tumor-derived	NULL
macrophages	NULL
suppresses	NULL
the	NULL
expression	NULL
of	NULL
CD3Â¢	NULL
chain	NULL
of	NULL
T-cell	NULL
receptor	NULL
complex	NULL
and	NULL
antigen-specific	NULL
T-cell	NULL
responses	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
:	NULL
13119-13124	NULL
,	NULL
1996	NULL
.	NULL

40	NULL
.	NULL

Guarini	NULL
,	NULL
A.	NULL
,	NULL
Riera	NULL
,	NULL
L.	NULL
,	NULL
Cignetti	NULL
,	NULL
A.	NULL
,	NULL
Montacchini	NULL
,	NULL
L.	NULL
,	NULL
Massaia	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Foa	NULL
,	NULL
R.	NULL
Transfer	NULL
of	NULL
the	NULL
interleukin-2	NULL
gene	NULL
into	NULL
human	NULL
cancer	NULL
cells	NULL
induces	NULL
specific	NULL
antitumor	NULL
recognition	NULL
and	NULL
restores	NULL
the	NULL
expression	NULL
of	NULL
CD3/T-cell	NULL
receptor	NULL
associated	NULL
signal	NULL
transduction	NULL
molecules	NULL
.	NULL

Blood	NULL
,	NULL
89	NULL
:	NULL
212-218	NULL
,	NULL
1997	NULL
.	NULL

41	NULL
.	NULL

Ling	NULL
,	NULL
W.	NULL
,	NULL
Rayman	NULL
,	NULL
P.	NULL
,	NULL
Uzzo	NULL
,	NULL
R.	NULL
,	NULL
Clark	NULL
,	NULL
P.	NULL
,	NULL
Kim	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Tubbs	NULL
,	NULL
R.	NULL
,	NULL
Novick	NULL
,	NULL
A.	NULL
,	NULL
Bukowski	NULL
,	NULL
R.	NULL
,	NULL
Hamilton	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Finke	NULL
,	NULL
J	NULL
.	NULL

Impaired	NULL
activation	NULL
of	NULL
NFKB	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
a	NULL
subset	NULL
of	NULL
renal	NULL
cell	NULL
carcinoma	NULL
patients	NULL
is	NULL
mediated	NULL
by	NULL
inhibition	NULL
of	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
of	NULL
the	NULL
inhibitor	NULL
,	NULL
IxBa	NULL
.	NULL

Blood	NULL
,	NULL
92	NULL
;	NULL
1334-1341	NULL
,	NULL
1998	NULL
.	NULL

Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Clinical	NULL
Cancer	NULL
Research	NULL
Signal	NULL
transduction	NULL
abnormalities	NULL
in	NULL
T	NULL
lymphocytes	NULL
from	NULL
patients	NULL
with	NULL
advanced	NULL
renal	NULL
carcinoma	NULL
:	NULL
clinical	NULL
relevance	NULL
and	NULL
effects	NULL
of	NULL
cytokine	NULL
therapy	NULL
.	NULL

R	NULL
M	NULL
Bukowski	NULL
,	NULL
P	NULL
Rayman	NULL
,	NULL
R	NULL
Uzzo	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Clin	NULL
Cancer	NULL
Res	NULL
1998	NULL
;	NULL
4:2337-2347	NULL
.	NULL

Updated	NULL
version	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//clincancerres.aacrjournals.org/content/4/10/2337	NULL
E-mail	NULL
alerts	NULL
Reprints	NULL
and	NULL
Subscriptions	NULL
Permissions	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//clincancerres.aacrjournals.org/content/4/10/2337	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

